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Type 2 diabetes mellitus (T2DM) and heart failure (HF) are diseases that 
commonly co-exist and have been shown to increase mortality. There is a 
variety of treatment options available to treat T2DM, however in the context of 
HF, many have been shown to not have any beneficial effects on reducing 
morbidity or mortality, while some are demonstrably harmful.  
The sodium-glucose linked co-transporter type 2 (SGLT2)-inhibitor class of 
drug was developed as a novel anti-diabetic agent that acts independent of 
the insulin-incretin pathway to lower blood sugar. Part of the off-target effects 
that have been seen with this drug class include weight loss, blood pressure 
reduction and diuresis – all of which are key in reducing cardiovascular risk, 
particularly in HF.  
An unexpected but consistent finding in large cardiovascular outcome trials 
(which are now mandatory for all new anti-diabetic agents) across the entire 
SGLT2-inihbitor class was that of improved HF outcomes. The mechanism of 
this effect was poorly characterised and required further exploration.  
The Research into the Effect of SGLT2-inhibiton on Left Ventricular 
Remodelling in Patients with Heart Failure and Diabetes Mellitus (REFORM) 
trial, addresses the literature gap in this area, and is the first to study the effects 
of SGLT2-inhibition specifically in the HF population. It showed no difference 
between groups in the primary endpoints of left ventricular (LV) end diastolic 
volume or LV end systolic volume; +4.15 ml; 95%CI: -18.52 to 26.83; p=0.714 
and +0.96 ml; 95%CI: -17.07 to 19.00; p=0.915 respectively. Patients on 
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dapagliflozin had weight reduction; -1.97kg; 95%CI: -3.99 to 0.05; p=0.056 
lower diastolic blood pressure; -6.58mmHg; 95%CI: -11.93 to-1.23; p=0.017 
higher haemoglobin; +1.16 g/dL; 95%CI: 0.60 to 1.74; p<0.001 and increased 
serum beta-hydroxybutyrate; +0.04 mmol/L; 95%CI: 0.001 to 0.08; p=0.045. 
They were also more likely to stop or reduce their dose of loop diuretics; 50.0% 
vs 8.7%; p=0.005. Further exploratory analysis revealed that dapagliflozin may 
improve measures of LV remodelling in patients with baseline LV ejection 
fraction of 45% or more.  
We have demonstrated, for the first time, that the effects of dapagliflozin seen 
previously in the T2DM population remains consistent in the HF population 
with T2DM. We have also have generated new avenues of research to improve 
our understanding of this drug class and its potential future use.  
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1. INTRODUCTION  
1.1 TYPE 2 DIABETES; A GROWING EPIDEMIC   
1.1.1 Defining and diagnosing diabetes 
The World Health Organisation (WHO) has published guidelines for the 
diagnosis and classification of diabetes since 1965. In its most recent iteration 
in 2006, the WHO defines diabetes as “a condition primarily defined by the 
level of hyperglycaemia giving rise to microvascular damage (retinopathy, 
nephropathy and neuropathy). It is associated with reduced life expectancy, 
significant morbidity due to specific diabetes related microvascular 
complications, increased risk of macrovascular complications (ischaemic heart 
disease, stroke and peripheral vascular disease), and diminished quality of 
life.”(2) The most current diagnostic criteria for diagnosing diabetes is 
summarised in Table 1. 
 
Table 1. Diagnostic criteria for diabetes mellitus(3) 
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FPG=Fasting plasma glucose; PG=Plasma glucose; OGTT=Oral glucose tolerance 
test; WHO=World Health Organisation; DCCT=Diabetes control and complications 
trial; NGSP= National Glycohemoglobin Standardization Program 
 
There are four broad types of diabetes, namely Type 1 diabetes (due to 
autoimmune pancreatic beta cell destruction leading to absolute insulin 
deficiency) , Type 2 diabetes (due to progressive loss in pancreatic beta cell 
function, on the background of insulin resistance), Gestational Diabetes 
(diabetes diagnosed in the second or third trimester of pregnancy in an 
individual not previously known to have diabetes) and specific types of 
diabetes due to secondary causes (such as neonatal diabetes, maturity-onset 
diabetes of the young, disease of the exocrine pancreas [such as cycstic 
fibrosis and pancreatitis] and drug / chemical induced diabetes [such as 
glucocorticoid use, treatment of HIV/AIDS or after organ transplantation])(3) 
The class of diabetes considered in this work is limited to that of Type 2 




1.1.2 Incidence and prevalence of Type 2 diabetes  
In 2016 the WHO published its Global Report on Diabetes which showed the 
global prevalence of all types of diabetes in 2014 was 8.5%, representing 422 
million individuals. This report also revealed diabetes was directly responsible 
for 1.5 million deaths in 2012, with a further 2.2 million deaths due to 
cardiovascular disease, chronic kidney disease and other conditions related to 
higher than normal blood glucose levels.(4) T2DM is by far the commonest 
type of diabetes and a recent study analysing published data from 45 countries 
representing nearly 90% of the world’s population estimates that in 2018 there 
are 500 million prevalent cases of T2DM. They project the greatest growth in 
T2DM prevalence will be in low-income countries over the next 10 years, which 
will greatly increase the burden on already strained health services in those 
countries.(5) 
Diabetes-UK states that diabetes is the fastest growing healthcare threat the 
United Kingdom is facing. In its facts and stats update 2019, it estimates 4.7 
million people have diabetes in the UK, including 1 million who are unaware of 
the disease as they remain undiagnosed.(6) The 2016 Scottish Diabetes 
Survey revealed there are nearly 300,000 individuals with diabetes in Scotland 
(prevalence 5.4%), with 88.3% of them having T2DM. The incidence of T2DM 




1.1.3 Type 2 diabetes and cardiovascular disease   
There is a well-recognised link between T2DM and cardiovascular disease 
(CVD). The pathophysiology that triggers the development of CVD starts well 
before a patient develops frank T2DM. Prediabetes is a term used for 
individuals whose glycaemic level does not fulfil criteria for diagnosing 
diabetes but is too high to be considered normal. Impaired fasting glucose 
(IFG) and impaired glucose tolerance (IGT) are two clinical conditions by which 
prediabetes manifests itself.(3) The diagnostic criteria for prediabetes is 
summarised in Table 2.  
 
Table 2. Diagnostic criteria for prediabetes(3) 
FPG=Fasting plasma glucose; IFG=Impaired fasting glucose; OGTT=Oral glucose 
tolerance test; IGT=Impaired glucose tolerance  
 
In the past, the cut-off for diagnosing diabetes was thought to represent the 
threshold of risk for developing microvascular pathology and thus CVD. We 
now recognise that no such threshold exists, and that CV risk is more of a 
spectrum, becoming disproportionately greater the higher the degree of 
hyperglycaemia.(3,8) Insulin resistance is the hallmark of prediabetes and 
underpins many of the pathophysiological processes associated with it. 
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Additionally, prediabetes is strongly associated with central obesity, 
hypertension, hypertriglyceridemia and or low HDL; the so-called metabolic 
syndrome, which is itself associated with increased microvascular and 
macrovascular risk.(9)    
Subclinical inflammation has been strongly associated with prediabetes and 
insulin resistance, as both the inflammatory and insulin signalling pathways 
are very closely linked to each other.(10)  Elevated levels of high sensitivity-C 
reactive protein, interleukin (IL)-1, IL-6 and tumour necrosis factor (TNF)-α 
have been shown in individuals with prediabetes, especially those who are at 
high risk of developing T2DM.(11) These cytokines, in turn, inhibit  
phosphatidylinositol 3-kinase dependent signalling of nitric oxide (NO) 
synthesis. Additionally, insulin resistance and hyperglycaemia results in 
increased free fatty acid (FFA), reactive oxygen species (ROS) and 
endothelin-1.(12,13) This combination of impaired NO synthesis, elevated 
ROS and increased levels of the potent vasoconstrictor endothelin-1 results in 
endothelial dysfunction. Indeed, endothelial dysfunction is the earliest 
manifestation of glycaemia-related vascular disease.(14)  
Insulin resistance is also associated with several changes in lipid and 
lipoprotein levels. As an individual with prediabetes progresses into frank 
T2DM, elevated very low density lipoprotein (VLDL)-triglycerides and reduced 
high density lipoprotein (HDL)-cholesterol (and by extension, apolipoprotein 
A1 which is the major apolipoprotein in HDL) is commonly seen.(15,16) 
Importantly, HDL and apolipprotein-A1 are responsible for the removal of 
excess cholesterol from monocyte-derived macrophages (cholesterol ester-
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engorged macrophages are also known as foam cells).(17) Although total 
cholesterol and low density lipoprotein (LDL) are frequently normal in patients 
with T2DM, there are compositional changes in the LDL by way of increased 
small dense LDL particles (which are the result of increased VLDL-
triglycerides) and an increase in the absolute number of LDL particles. Small 
dense LDL particles readily enter the arterial wall, cause increased synthesis 
of procoagulants and are more easily oxidised than larger particles.(14) This, 
along with the pro-inflammatory state discussed above accelerates 
atherosclerosis, which is one of the key pathological changes in cardiovascular 
disease.     
Insulin resistance and T2DM increases thrombotic risk via multiple 
mechanisms. Insulin resistance is associated with elevated levels of 
plasminogen activator inhibitor-1 (PAI-1) which supresses fibrinolysis.(18) 
Numerous studies have also linked the pathophysiologic process of T2DM 
(e.g. pro-inflammatory state, altered lipoprotein profile) with increased 
coagulation factors VII, VIII, XII and fibrinogen.(19) T2DM also affects platelet 
function. Insulin antagonises the action of adenosine diphosphate, platelet 
activating factor and collagen on platelet cell surface receptors, thereby 
preventing platelet activation and aggregation. Although hyperinsulinemia is a 
feature of T2DM (and one could therefore expect to see an anti-platelet effect), 
numerous studies have shown platelet aggregation is actually upregulated in 
the context of insulin resistance, suggesting that the effect of insulin resistance 
supersedes that of hyperinsulinemia in this regard.(18,20-22) Finally, healthy 
endothelial cells produce anti-aggregants such as NO and prostacyclin I-2 
(PGI2). The endothelial dysfunction resulting from insulin resistance and T2DM 
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supresses the production of these molecules and tips the balance toward 
platelet aggregation and thrombosis.(19) 
It has long been argued that patients with T2DM develop HF as a result of 
diabetes induced-cardiovascular disease or a complication from it such as 
hypertension or a myocardial infarction. Although that may certainly be a 
contributing factor, there has been a recent recognition that diabetes itself, by 
neuro-hormonal, metabolic, inflammatory, microvascular and bio-energetic 
pathways, may be directly responsible for HF – this will be explored in more 




1.2 THE GROWING BURDEN OF HEART FAILURE 
1.2.1 Defining and diagnosing heart failure  
The 2016 European Society of Cardiology Guidelines for the diagnosis and 
treatment of acute and chronic heart failure defines HF as a “clinical syndrome 
characterized by typical symptoms that may be accompanied by signs caused 
by a structural and/or functional cardiac abnormality, resulting in a reduced 
cardiac output and / or elevated intracardiac pressures at rest or during 
stress.”(23) Heart failure is primarily a clinical diagnosis that is supported by 
investigative findings to prognosticate the disease, identify other co-
morbidities and to determine the underlying aetiology, which in some cases 
may be reversible.   
The key in diagnosing HF is the presence of typical symptoms of 
breathlessness, fatigue, oedema, orthopnoea and paroxysmal nocturnal 
dyspnoea (PND) which are frequently associated with evidence of an elevated 
jugular venous pulse (JVP), third heart sound, crackles in the lungs and 
peripheral oedema.  
An important, albeit subjective, clinical measure of determining the symptom 
burden of HF is the NYHA functional classification. The NYHA classification 
was first described in 1928, then developed further in 1964 into the 4-
numerical-class system used till today in clinical practice and cardiovascular 
research. To address the subjective nature of the NYHA classification (a 
limitation recognised by the 1964 Criteria Committee when they described the 
system as “only approximate, for it is derived largely by inference from the 
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history, by observation of the patient in certain forms of physical activity, and 
occasionally by direct or indirect measurement of cardiac function in response 
to standardized exercises. It represents an expression of [the provider's] 
opinion…”), a further ‘objective assessment’ criteria (classes A to D) was 
added to the system in 1994.(24) This additional criterion uses measures such 
as electrocardiogram (ECG), x-rays, echocardiograms and other radiologic 
assessments to classify the severity of cardiac structural and functional 
abnormality from ‘no objective evidence of cardiovascular disease’ (Class A) 
to ‘objective evidence of severe cardiovascular disease’ (Class D). Therefore, 
a complete evaluation should include the patient’s functional capacity (Class I 
to IV) and objective assessment (A to D). (Table 3) Although using both criteria 
increases the reliability of the NYHA classification, the objective assessment 
component is rarely quoted in routine clinical practice.(25) 
 





B-type natriuretic peptide (BNP) and the amino terminal portion of its 
precursor, proBNP (NT-proBNP) are cardiac biomarkers that have now been 
widely accepted as tools to assist in the workup for HF. BNP is released 
predominantly in the ventricles in response to myocardial stretch as a result of 
increased end-diastolic pressure and/or volume.(26,27) It plays a prominent 
role in the compensatory response to HF by way of increased natriuresis, 
diuresis, vasodilation as well as inhibiting the sympathetic nervous system (by 
reduced catecholamine secretion) and the renin-angiotensin-aldosterone 
system (RAAS) (by reduced renin secretion).(28) Patients with normal 
concentrations of BNP / NT-proBNP are unlikely to have HF. Cut-offs of 35 
pg/mL for BNP and 125 pg/mL for NT-proBNP in the chronic setting and 100 
pg/mL and 300 pg/mL respectively in the acute setting have a negative 
predictive value between 0.94 and 0.98.(29-31) It is important to note that 
these biomarkers have much lower positive predictive values, and therefore 
their main use should be in ruling out HF rather than establishing the 
diagnosis.(23) There has been interest in using BNP / NT-proBNP to 
objectively track patients’ response to therapy but the data have been mixed; 
there is evidence to suggest that it correlates to improvements in clinical and 
objective markers of congestion (such as jugular venous pulsation, 
orthopnoea, weight, inferior vena caval diameter and pulmonary capillary 
wedge pressure) (32) but not to improvements in hard outcomes such as 
hospitalisation for HF or CV mortality.(33) 
As discussed above, another important aspect of assessing heart failure 
includes imaging the heart to determine the degree of functional impairment 
as well as to identify structural abnormalities that may be responsible for, or 
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the result of, the heart failure. Echocardiography, which is an inexpensive, 
accurate and accessible tool, is the mainstay in this regard. Advancements in 
echocardiography technology and technique now mean that detailed 
assessments of systolic and diastolic function can be made, and overall 
ventricular function (measured as ejection fraction [EF]) can be measured to a 
high degree of reliability. More recently this has led to further subclassifying 
heart failure, according to degree of LV dysfunction, to heart failure with 
reduced ejection fraction (HFrEF), heart failure with mid-range ejection fraction 
(HFmrEF) and heart failure with preserved ejection fraction (HFpEF) with 
echocardiographic LVEF cut-offs of <40%, 40-49% and ≥ 50% 
respectively.(23) This is an important distinction because patients in these 
different categories (particularly in the case of HFrEF vs HFpEF) have different 
aetiologies, co-morbidities, prognosis and response to therapy.(23,34) 
An important but frequently overlooked part of the diagnostic workup for HF is 
establishing the underlying aetiology. This is important because it may reveal 
reversible aetiologies such as cardiotoxicity from alcohol / drugs, comorbidities 
like severe anaemia, thyroid disease, valvular heart disease or even nutritional 
deficiencies. In some cases, these investigations may also reveal a heritable 
disease such as familial dilated cardiomyopathy or arrhythmogenic right 
ventricular cardiomyopathy which will have implications to the patient’s family 





Table 4. Aetiologies of heart failure(23) 
ARVC=Arrhythmogenic right ventricular cardiomyopathy; DCM=Dilated 
cardiomyopathy; EMF=Endomyocardial fibrosis; GH=Growth hormone; 
HCM=Hypertrophic cardiomyopathy; HES=Hypereosinophillic syndrome; 





1.2.2 Incidence and prevalence of heart failure  
HF has been identified as a growing global epidemic with approximately 26 
million people with the disease worldwide in 2014.(35) The incidence of HF is 
difficult to quantify due to variations in the diagnostic criteria and method of 
detection. Inconsistencies in hospital coding, including ‘upcoding’ for financial 
incentive and an inability to distinguish between first and subsequent 
admissions have been blamed. Additionally, the increasing use of outpatient 
care for HF mean inpatient data (which forms the bulk of epidemiological data 
in HF) is unable to capture the true burden of incidence.(36) As a 
consequence, reported incidence range from 1.0 to 26.0 per 1000 person-
years depending on age, gender, ethnicity and geographical location, with the 
highest incidence seen in elderly males of Afro-Caribbean decent.(36) 
In developed nations the prevalence of HF is approximately 1-2% of the adult 
population. This rises to more than 10% in individuals above the age of 
70.(23,37) It is also the commonest cause of hospitalisation in patients above 
the age of 65.(38) In the UK, more than 500,000 people have HF and the 
burden of treating this disease is large; accounting for 1-2% of the NHS’s 
overall budget with up to 70% of that cost related to hospitalisation alone.(39) 
A similar picture is seen in the United States with HF accounting for 1 million 
hospitalisations annually with an average duration of hospitalisation between 
5 to 7 days depending whether it is a primary or secondary (related to co-




1.2.3 Pathophysiology of heart failure   
The pathophysiology behind HF varies depending on the underlying aetiology, 
or in some cases, aetiologies. When one recognises that HF is a syndrome 
rather than a disease in and of itself, it is easy to understand how (and why) 
multiple mechanisms are at play in causing HF. Some examples of these 
mechanisms (or models) include the haemodynamic, cardio-renal, 
neurohormonal, abnormal calcium cycling and cell death models.  
The haemodynamic model is well-known and using the Frank-Starling 
principal, it provides a mechanical understanding of the effects of excessive 
increases in intraventricular end-diastolic volume and stretch on cardiac 
contractility. In 1967 Eugene Braunwald and colleagues demonstrated 
decreasing intrinsic contractility of the myocardium with increasing 
haemodynamic load using isolated cardiac muscles from cats with heart 
failure.(41)  The extracellular matrix (ECM) is an important determinant of the 
ventricular architecture, and by extension, its function. Remodelling of the 
ECM from an insult like a myocardial infarction results in fibrosis and thinning 
of the ventricular wall resulting in altered ventricular loading dynamics. 
Additionally, the loss of contractile tissue also contributes directly to poorer 
inotropy. (See cell death model below)(42) Conversely, excessive ECM 
synthesis stimulated by uncontrolled hypertension and/or persistent activation 
of the RAAS (and resultant aldosterone excess) result in ventricular 
hypertrophy causing impaired relaxation (ventricular filling) and contraction 
(ventricular emptying). These changes result in HF albeit with a preserved EF; 
the so-called HFpEF.(43) 
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The kidneys play an integral role in the HF syndrome. The cardio-renal model 
describes the kidney’s role in sodium and fluid homeostasis which is directly 
related to congestion and the manifest symptoms of HF. Equally, renal function 
is also dependent on cardiac function; reduced renal blood flow to the 
glomerulus (and even renal ischaemia in severe cases) from impaired forward 
flows and peri-renal congestion from increased back pressure are seen in HF. 
These changes in renal haemodynamics have been established as the primary 
driving mechanisms of renal impairment in patients with HF.(44,45) (Figure 1) 
A further interplay between these two organs relate to the effects of anti-HF 






Figure 1. Cardio-renal model of heart failure(45) 
RAAS=Renin-angiotensin-aldosterone system; ANP=Atrial natriuretic peptide; 
BNP=B-type natriuretic peptide; GFR=Glomerular filtration rate 
 
The neurohormonal system is an important determinant of cardiac 
performance. Seminal work, once again, by Professor Braunwald and 
colleagues performed in the mid-20th century established the role of the 
sympathetic nervous system in augmenting cardiac performance during 
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exercise and states of increased demand.(46) In the acute setting, the 
sympathetic nervous system and the RAAS increases cardiac contractility, 
induces vasoconstriction and anti-natriuresis resulting in improved BP and 
perfusion of vital organs, thereby compensating for the LV dysfunction.(47) 
However, sustained activation of the neurohormonal system results in 
maladaptive remodelling of the ventricles and myocardial injury causing further 
impairment of LV function, thus setting up the vicious cycle that is the hallmark 
of the neurohormonal model of HF.(42) (Figure 2)   
A common feature of all the pathophysiological models discussed above is the 
compensatory mechanisms to a failing heart results in a spiral of adverse 
remodelling within the myocardium which then perpetuates the diseased state. 
Deranged myocardial calcium homeostasis is yet another maladaptive 
response to ventricular hypertrophy, increased LV end diastolic pressure and 
sustained RAAS activation.(48) Intracytoplasmic calcium in the cardiac 
myocyte plays a key role in myocardial contractility as well as in maintaining 
the electrical stability of the heart.(49) Dysregulation of calcium flux due to 
dysfunctional ryanodine receptors (RyR2) and the sarcoendoplasmic reticular 
adenosine triphosphate–driven calcium (SERCA2a) pump alters 
intracytoplasmic and sarcoendoplasmic calcium concentration and results in 
weaker myocardial contractility(50) and ventricular tachyarrhythmias. (51,52) 
All HF syndromes are associated with increased cardiac myocyte death.(53) 
As discussed above, this may be the result of abnormal loading conditions, 
excessive adrenergic activity, prolonged RAAS activation and remodelling, 
deranged calcium handling or even other factors such as direct cellular 
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damage from radiation, infiltration (amyloid, sarcoid, glycogen or lysosomal 
storage disorders), and toxins such as alcohol or chemotherapeutic agents. In 
other scenarios, autophagy which is a physiological and protective process of 
intracellular organelle recycling, may be maladaptively upregulated in 
instances of increased pressure loading leading to unrestrained cell death.(54) 
Whereas in the elderly, autophagic activity declines resulting in intracellular 
accumulation of protein aggregates and lipofuscin. These by-products of 
cellular function lead to increased oxidative stress, impaired cellular 
metabolism and eventually cell death.(55) 
Apart from these classical (generic) mechanisms, there are other more 
aetiology-specific mechanisms such as the genetic model relating to various 
inherited cardiomyopathies, the immune model relating to auto-immune and 
infective cardiomyopathies and the diabetic model which will be discussed in 




Figure 2. Loss of RAAS negative feedback in heart failure. 
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1.3 HEART FAILURE AND DIABETES; A LETHAL COMBINATION  
 
1.3.1 The diabetic heart  
 
As discussed in the preceding chapters, the prevalence of T2DM and HF 
continue to increase. Worryingly, these two potentially lethal conditions in their 
own right also commonly co-exist; up to 45% of patients with chronic HF have 
concomitant T2DM.(56) In a population-based study of individuals 65 years or 
older, the 5 year survival of a diabetic patient with a new diagnosis of HF was 
12.5% compared to over 80% if they remained free of HF. The same study 
also showed males and Caucasians fared worse than females and Blacks.(57)  
Registry data seem to suggest there is no difference in the outcomes of 
patients with or without T2DM presenting with acute HF. The Acute 
Decompensated Heart Failure National Registry (ADHERE) showed no 
difference in in-hospital mortality between both groups, while the Organized 
Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart 
Failure (OPTIMIZE-HF) registry did show slightly longer hospitalisations (5.9 
vs 5.5 days; p<0.0001), but no mortality difference up to 90 days post 
discharge (note only 10% of patients were followed up to 90 days).  
However in a large, contemporary, prospective analysis of this cohort, Sarma 
et al looked at data from the Efficacy of Vasopressin Antagonism in Heart 
Failure Outcome Study with Tolvaptan (EVEREST) trial and found patients 
with T2DM had higher combined endpoints of CV mortality or HF 
hospitalisation (HR 1.17; 95% CI 1.04–1.31) for a median of 9.9 months 
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following discharge for an acute presentation of HF with low ejection fraction, 
compared to those who did not have T2DM.(58) (Figure 3) These data are 
more in keeping with the long term, population-based studies that clearly 
showed a stark difference in mortality when T2DM and HF co-exist.  
 
Figure 3. Long term outcomes of patients with or without T2DM following HF 
hospitalisation(58) 
 
Interestingly there is a bidirectional risk for T2DM and HF. Patients with T2DM 
have been shown to have an 8% increase risk of HF for every 1% rise in 
HbA1c.(59) Similarly, patients with chronic HF have markedly increased 
insulin resistance, which increases their risk for developing T2DM compared 
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to healthy individuals or even those with coronary artery disease.(60) In the 
following sections we will explore how these two conditions interact and form 
a lethal combination.  
 
1.3.2 Diabetes causing heart failure  
Following on from the observation of increased mortality and morbidity when 
T2DM and HF co-exist, it is important to understand the pathophysiology 
driving this increased risk in patients. Diabetic cardiomyopathy is now 
becoming more recognised as a pathophysiological entity of its own. Until 
recently, most authors believed that heart failure was the long-term 
manifestation of accelerated CV disease due to diabetes, however with a 
clearer understanding of the molecular pathways that are affected by T2DM, 
we now recognise how the metabolic, inflammatory, microvascular and neuro-
hormonal changes caused by diabetes can result in de-novo cardiomyopathy; 




Figure 4. Pathophysiology of Diabetic Cardiomyopathy(61) 
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One of the earliest metabolic changes seen is the switch of myocardial fuel 
balance away from glucose toward FFA. In the healthy heart, cardiomyocytes 
are able to freely switch between glucose, FFA, lactate, ketones and other fuel 
substrates depending on fuel availability, workload and tissue perfusion.(62) 
In a state of rest, the healthy heart predominantly uses FFA as a fuel substrate 
because of its dense energy content. However, during periods of increased 
workload, glucose is preferred as it is a far more oxygen-efficient fuel; although 
it may liberate less energy per molecule compared to FFA, it has a better 
energy yield per oxygen atom consumed. (Table 5)  
 
Table 5. Fuel energetics of various substrates(62) 
ATP-Adenosine triphosphate; BHOB-Beta-hydroxybutyrate; P/O-Phosphate-oxygen 
  
Similarly, under hypoxic conditions such as myocardial ischaemia or in the 
failing myocardium, there is an adaptive and cardio-protective response that 
favours glucose as the primary fuel substrate via enhanced glucose uptake, 
activation of glycolytic pathway enzymes and reduction of FFA 
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oxidation.(61,62) By switching the fuel substrate, the heart is able to reduce 
the supply-demand mismatch and improve myocardial contractile efficiency by 
increasing the energy production-to-oxygen consumption ratio.  
In patients with insulin resistance and T2DM, this ability to switch to a 
predominantly glucose fuel substrate is lost. Insulin resistance reduces the 
efficiency of the GLUT-4 glucose transporter protein which is responsible for 
glucose uptake into the cell.(63) Additionally, there is increased delivery of 
FFA as a result of enhanced lipolysis and peripheral insulin resistance.(64) 
Longstanding elevation in intra-myocyte FFA levels activate the nuclear 
receptor peroxisome proliferator-activated receptor-alpha (PPAR- α), which in 
turn results in increased mitochondrial FFA transport and oxidation; thereby 
fixing the myocyte into a FFA-based fuel substrate. FFAs also impair the 
intracellular insulin signalling pathways, consolidating the insulin resistance of 
the myocyte and relegating glycolytic pathways even further. Indeed in a 
recent small study (n=18) using positron emission tomography to measure 
myocardial FFA consumption with 16-[18F] fluoro-4-thia-palmitate (FTP) in 
patients with or without T2DM, Mather et al. demonstrated increased 
myocardial FFA oxidation in patients with T2DM and a failure to fully suppress 
myocardial FFA oxidation in hyperinsulinemic-euglycaemic clamp. This 
reflected the persistently elevated rates of myocardial FFA transport 
contributed by activation of PPAR- α. They also observed reduced myocardial 
work efficiency in the T2DM group, which they postulated was the result of 




Apart from predisposing to an adverse myocardial energetic profile, lipotoxicity 
is another potential factor contributing to diabetic cardiomyopathy. When 
myocardial FFA uptake outpaces its β-oxidation capacity, the excess FFA is 
converted to triacylglycerol (TG) leading to cardiac steatosis. Additionally, 
there is also accumulation of potentially toxic by-products of β-oxidation such 
as diacylglycerol (DAG) and ceremide.(66) This intra-myocyte build-up of TG, 
DAG and ceremide generates ROS. Early changes of ROS damage are seen 
in the sarcoplasmic (endoplasmic) reticulum, where there is inactivation of its 
calcium-ATPase.(67) This results in reduced sequestration of calcium in the 
sarcoplasmic reticulum and a cytosolic calcium overload, which in turn causes 
myocardial fibrosis, hypertrophy and diastolic dysfunction.(66) Further 
accumulation of ROS induces mitochondrial uncoupling (dysfunction) and 
eventually apoptosis.(61)  
Other non-metabolic factors contributing to the pathophysiology of diabetic 
cardiomyopathy include microvascular dysfunction, neurohormonal activation 
and autonomic dysfunction. Advanced glycated end-products are a well 
described vascular sequala of T2DM resulting in microvascular remodelling, 
impaired nitric oxide production and endothelial dysfunction. The consequent 
myocardial ischaemia contribute to myocyte necrosis, fibrosis and 
hypertrophy.(61) Insulin resistance and T2DM have also been implicated with 
sympathetic activation as well as upregulation of the RAAS which are 
deleterious to the heart due to increased cardiac fibrosis, apoptosis, vascular 




1.3.3 Heart failure causing diabetes  
The risk of cardiovascular disease due to T2DM is well recognised but the risk 
of developing T2DM from established HF is less well studied. Recent work, 
however, has demonstrated increasing risk of insulin resistance with 
worsening New York Heart Association (NYHA) functional class in non-
diabetic patients with HF(70) as well as increased incidence of T2DM with 
worsening NYHA functional class in post myocardial infarction (MI) and elderly 
HF patients.(71,72)  
The exact mechanisms behind this observation are still being elucidated, but 
there are numerous hypotheses that suggest neurohormonal, haemodynamic 
or even iatrogenic causes to this.  
HF induces a maladaptive increase in sympathetic outflow and RAAS 
activation. Sympathetic activation has been shown to reduce insulin-mediated 
glucose uptake into skeletal muscles by 25% (peripheral insulin resistance) 
and increase lipolysis resulting in elevated FFA levels. Increased FFA levels 
worsen insulin resistance by impairing intracellular insulin signalling pathways 
and increasing hepatic gluconeogenesis, further worsening hyperglycaemia. 
Additionally catecholamines also inhibit pancreatic insulin secretion and 
stimulate hepatic gluconeogenesis and glycogenolysis compounding the 
hyperglycaemic state.(73) RAAS activation has been implicated with the 
development of diabetes by way of angiotensin II and aldosterone-induced 
insulin resistance due to increased oxidative stress and altered intracellular 
insulin signalling. Aldosterone has also been shown to reduce insulin secretion 
from isolated pancreatic islets and cultured beta-cells while angiotensin II has 
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been implicated with pancreatic beta-cell apoptosis.(74) Additionally, 
subgroup analysis of RAAS-modulating anti-HF therapy such as enalapril in 
the Studies of Left Ventricular Dysfunction (SOLVD) trial and candesartan in 
the Candesartan in Heart Failure-Assessment of Reduction in Mortality and 
Morbidity Program (CHARM) trial showed lower risk of developing T2DM in 
the treatment arms; HR 0.22 (0.10–0.46, P<0.0001) and HR 0.78 (0.64–0.96, 
P=0.02) respectively.(75,76) These findings lend credence to the theory that 
RAAS activation is involved in the development of T2DM.  
The haemodynamic hypothesis proposes impaired perfusion and increased 
congestion of the pancreas and liver resulting in deranged glucose 
homeostasis. A study involving 50 patients from a single centre who 
underwent left ventricular assist device (LVAD) implantation showed 
significant and sustained reduction in HbA1c up to 1-year post implant.(77) 
Although not definitive and open to confounding, this study supports the 
haemodynamic hypothesis. Another potential mechanism is that of skeletal 
muscle atrophy and the resultant reduced physical activity associated with HF 
may predispose to a more sedentary lifestyle and, indirectly, to insulin 
resistance and T2DM.  
As more drug classes were licenced for use with HF, there was increasing 
interest in the potential side-effect profile of these agents, especially around 
developing T2DM. There was conflicting evidence on this, compounded by 
significant heterogeneity in meta-analyses comparing the effects of different 
drug classes. A network meta-analysis (which is able to overcome the issue of 
heterogeneity due to differing treatment strategies and indirect comparisons of 
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multiple agents) of various anti-hypertensive agents involving more than 
140,000 patients from 22 clinical trials (only 1 of them on patients with HF) 
indeed did show a protective effect of ACE-i and ARB as well as an increased 
risk of incident T2DM in patients using diuretics and beta-blockers.(78) In the 
case of beta-blockers potential mechanisms include direct inhibitory effects on 
pancreatic beta-cell insulin release and increased peripheral insulin 
resistance, while patients on diuretics may develop hypokalemia causing 
reduced insulin secretion.(79) 
This bidirectional relationship of T2DM and HF requires the treating physician 
to always be vigilant of potential early signs of disease progression, if not 
already presenting with both co-morbidities together. It highlights the 
importance of understanding their intertwined pathophysiology (Figure 5) and 
underscores the urgent need for specific, targeted therapy for this unique 
group of patients. 
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NO=Nitric oxide; downward arrow= Reduced; AGE=Advanced glycated end-products; 
sideways arrow=resulting in; RAAS=Renin angiotensin-aldosterone system. 
 
Figure 5. Bidirectional relationship between Type 2 diabetes and heart failure 
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1.4 COMPLEXITIES OF TREATING T2DM AND HEART FAILURE  
1.4.1 Overview 
The last 3 decades have been a boon for managing T2DM, with rapid 
development of multiple anti-diabetes medications acting via various 
mechanisms. Although they all have proven efficacy in lowering fasting blood 
glucose and HbA1c, their impact on hard outcomes such as reducing CV risk 
(particularly macrovascular risk) and mortality have been less robust.(80-82)   
Of particular concern is their effect on patients with concomitant HF; in some 
instances, drug classes have a neutral effect on HF-related outcomes, while 
others may actually increase the risk of incident HF and CV mortality 
(discussed further in this chapter). We have previously shown in a cohort of 
patients with chronic HF that there is a U-shaped relationship between time-
weighted HbA1c and mortality – such that all-cause mortality starts to rise once 
HBA1c falls below 8% (Figure 6). Our work showed that this inverse 
relationship between mortality and HbA1c below 8% was most pronounced 
with the use of insulin and sulfonylureas (SU).(83) On the other hand, agents 
such as metformin have been shown to improve HF outcomes such as HF 
hospitalisation and mortality(84-86). Newer generation therapy such as 
glucagon like peptide (GLP)-1 agonists have also shown potential benefits by 
way of lower CV mortality.(87) 
There is a sense of inertia (and perhaps a degree of ignorance) amongst many 
physicians treating T2DM and HF which is rooted in the long-standing, but 
unsubstantiated, belief that merely lowering blood glucose will improve 
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outcomes. In this section we review the complexities (and potential dangers) 
of treating T2DM in patients who also have HF.  
 
 
Figure 6. Risk of all-cause mortality against time-weighted HbA1c in patients with 






1.4.2 Sulfonylureas  
SUs are insulin secretagogues and have long been used as second-line 
therapy in T2DM. Combined with metformin, SUs can lower HbA1c by as much 
as 24% compared to monotherapy but its cardiovascular safety, particularly in 
T2DM and HF patients remains questionable.(88) Various studies have shown 
an increased risk of CV events(89,90), weight gain and hypoglycaemia.(91) In 
a large observational study involving 91,000 patients, Tzoulaki highlighted an 
18 – 30% increased risk of developing incident HF when using SU as 
monotherapy compared with metformin alone.(92)  
Some of the suggested mechanisms of increased CV risk related to SU 
therapy include that of an inappropriate interaction with myocardial ATP-
sensitive potassium channels disrupting cardiomyocyte ability to recover from 
ischaemic injury.(93) Another hypothesis relates to frequent episodes of 
hypoglycaemia and sympathetic activation which is associated with excess 





Thiazolidinediones (TZD) target the PPAR-γ receptor to increase peripheral 
insulin sensitivity. They were welcomed as an alternative to SUs particularly 
because of a lower risk of hypoglycaemia. However, a timely meta-analysis by 
Nissen and Wolski involving 43 trials of rosiglitazone raised concerns about 
excess risk of myocardial infarction by 43% and CV death by 64%.(96) This 
triggered further scrutiny which also found 70% higher risk of incident HF with 
the use of TZDs.(97) These and work by others led the US-FDA to issue a 
black box warning regarding the use of rosiglitazone in patients with risk of 
IHD and the contraindication of prescribing any TZD in the setting of NYHA 
functional class III-IV HF.(98) 
The mechanisms of increased coronary artery disease remain controversial 
but revolves around its potential effect on cholesterol metabolism and the 
increase in serum LDL cholesterol levels.(99) The HF risk is more established 




1.4.4 DPPIV-Inhibitors    
DPP-IV inhibitors are classified as incretin modulators, which prolong the 
duration of action of GLP-1 by preventing its breakdown. These drugs 
modestly reduce HbA1c by an average of 0.7% (101), prolong beta-cell 
survival, are not associated with hypoglycaemia and are weight neutral.(102) 
After the CV concerns raised by TZDs, the US-FDA mandated CV outcome 
trials for all anti-diabetic therapy which prompted further investigation into this 
drug class. This came in the form of three large CV outcomes trials; the 
Sitagliptin Cardiovascular Outcomes Study (TECOS) (103), Does Saxagliptin 
Reduce the Risk of Cardiovascular Events When Used Alone or Added to 
Other Diabetes Medications (SAVOR - TIMI 53) (104) and Cardiovascular 
Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute 
Coronary Syndrome (EXAMINE) (105), which set out to test the CV efficacy of 
sitagliptin, saxagliptin and alogliptin respectively.  
All three trials were neutral in their primary outcome of major adverse 
cardiovascular events (MACE). However, in the case of SAVOUR-TIMI 53, 
saxagliptin was associated with a 27% increased risk of HF hospitalisation and 
22% excess CV mortality risk. A further meta-analysis of more than 95,000 
patients of 14 trials studying various glucose-lowering agents revealed those 
on DPPIV-inhibitors had a 25% increased risk of developing incident HF (HR 
1.25, 95% CI 1.08 -1.45).(106) 
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1.4.5 Insulin  
Insulin plays a central role in diabetes; T2DM management involves either 
increasing the body’s sensitivity to it, stimulating increased secretion from the 
pancreas or exogenous replacement of insulin. Exogenous administration of 
insulin has the most potent and direct effect on lowering blood glucose levels. 
However, as discussed above, this does not necessarily imply improved 
macrovascular benefits.  
The increased risk of hypoglycaemia events, sodium retention and weight gain 
has raised concerns around its use in patients with HF, however there has 
been no clinical trial to date specifically designed to investigate this. In a wide-
ranging analysis of four large HF clinical trials involving 24,000 patients and a 
further 100,000 patients with HF from an administrative database, Cosmi and 
colleagues found that  the use of insulin (alone or in combination with other 
agents) resulted in increased risk of all cause death HF hospitalisation by 27% 
and 23% in the trial population, while the patients from the administrative 




These signals of increased morbidity and mortality with the use of ‘mainstay’ 
anti-diabetic agents in the context of HF is concerning. It underscores the 
importance on focusing, not merely on glycaemic efficacy, but instead on a 
drug’s efficacy in reducing CV risk. Indeed, current generation anti-diabetic 
agents are addressing this head-on, most exciting of all is the newest 
member of the group; the SGLT2-inhibitor class.   
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1.5 SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS 
1.5.1 Glucose Transporters  
There are two broad classes of glucose transporters in man; the facilitated 
transporters/uniporters known simply as glucose transporter (GLUT) and the 
active transporters or symporters called the sodium-glucose linked 
cotransporter (SGLT) family. There are 14 known GLUT proteins classified into 
three subclasses according to similarities in their genetic sequences.(108) 
They all function in an energy independent manner, allowing bidirectional 
transport of their substrate across the cellular membrane. They each exhibit 
different transport kinetics that may be symmetric or asymmetric, which is 
outside the scope of this work.(109)  
SGLT proteins, on the other hand, mediate thermodynamically-coupled 
transport of sodium and glucose across the plasma membrane in an ATP-
dependent mechanism. The first description of this active transport of glucose 
was proposed by Robert Crane at the Symposium on Membrane Transport 
and Metabolism in Prague in 1960. (Figure 7) In his model, which has been 
validated and is still in use today, the ‘active’ transport of glucose is facilitated 
by the movement of sodium down its concentration gradient via the SGLT 
protein. The sodium gradient is maintained by a Na+/K+ pump, which is where 
the energy expenditure occurs - the movement across the SGLT protein itself 




Figure 7. Drawing by Robert Crane of his cotransport model on 24 August 1960 in 
Prague(111) 
 
A mechanical model for the sodium and glucose coupled transport has been 
described as a six-state rapid equilibrium, alternating access model. (Figure 
8) States 1 to 3 are outward facing, while 4 to 6 face inward. In the unloaded 
state the carrier is outward facing, has a negative charge and low affinity to 
glucose. Extracellular sodium binding to the carrier results in a conformational 
change that allows glucose binding. The tertiary structure of sodium, glucose 
and carrier then undergoes a conformational change that faces inwards. In this 
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state, the ligands are released intracellularly. With the release of the positively 
charged sodium ion, the carrier returns to a negative charge which results in a 
conformational change back to an outward facing state.   
 
 







There are six known isoforms of the SGLT protein, identified numerically from 
SGLT1 to SGLT6 and they can be found in varying concentrations throughout 
the human body in organs such as the kidneys, gut, liver, muscles, brain and 
heart. SGLT1 is predominantly found in the intestinal brush border but can also 
be found in the distal (S3) segment of the proximal convoluted tubules (PCT). 
SGLT3 has the most diffuse distribution throughout the body and is not strictly 
responsible for glucose transport per se but acts as a glucose sensor instead.  
The isoform of interest in this work is the SGLT2, which is concentrated in the 
first two segments (S1 and S2) of the PCT located in the renal cortex. mRNA 
expression assays have shown that SGLT2 proteins are almost exclusively 
expressed in the kidneys, although they may also be found in the pancreatic 
alpha cells, testes, prostate, heart and cerebellum. (Figure 9) (113,114) 
Figure 9. Expression of SGLT2 mRNA in human tissue samples.(112) 
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1.5.2 Renal glucose handling physiology 
The glomeruli of a healthy individual filter approximately 180g of glucose a day 
(approximately 30% of daily energy intake) and virtually all is reabsorbed with 
<1% being excreted.(113) The transport proteins responsible for this are the 
SGLT1 and SGLT2 transporters. SGLT2 is a low affinity, high capacity 
transporter that is responsible for approximately 90% of glucose reabsorption 
in the proximal segment of the PCT, while the remainder is performed by the 
high affinity, low capacity SGLT1 in the distal segment of the PCT. Renal 
tubular glucose reabsorption is a multistep process starting with SGLT-
mediated transport of glucose from the tubule into the tubular epithelial cells. 
This is followed by facilitated diffusion, down the concentration gradient, 
across the basolateral membrane into the peritubular capillaries via GLUT. 
(Figure 10)
 
Figure 10. Physiology of renal tubular glucose reabsorption.(115) 
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A healthy adult is able to handle renal tubular glucose reabsorption demands 
up to a blood glucose level of around 12 mmol/L.(116) Although there is 
considerable variation in this threshold, once an individual develops T2DM, it 
is routinely breached, resulting in glycosuria. In such conditions, the kidney 
responds by upregulating SGLTs and GLUTs; Rahmoune and colleagues 
performed an elegant study isolating and culturing human exfoliated proximal 
tubular epithelial cells from fresh urine. They demonstrated for the first time 
that isolates from patients with T2DM expressed significantly more SGLT2 and 
GLUT2 proteins than healthy individuals. They also showed increased glucose 
uptake in the cultured isolates of these cells from the T2DM patients.(117) This 
increase in the renal glucose reabsorption threshold is an evolutionary 
response in an attempt to conserve as much of this energy substrate, but is 
clearly counter-productive in T2DM as it sustains the hyperglycaemic state. 






1.5.3 Pharmacology of SGLT2-inhibitors 
In 1835 French chemists first isolated the flavonoid phlorizin from the bark of 
an apple tree. Later observations by von Mering showed that doses greater 
than 1 gm produced glycosuria. It achieves this by competing with D-glucose 
to non-selectively bind to both SGLT1 and SGLT2 proteins. Due to its effects 
on the SGLT1 protein in the intestine, phlorizin also causes osmotic diarrhoea, 
making it a poor pharmaceutical candidate.(118)  
It was only in 1999 that a team of Japanese researchers were able to modify 
the chemical structure of phlorizin to increase its selectively towards SGLT2 
while allowing for oral administration.(119) Since then there has been further 
evolution and distilling of this modification culminating in the current generation 
of highly selective SGLT2-inhibitors. As SGLT2 transporter proteins are 
predominantly renally expressed, these inhibitors selectively act on the 
kidneys to cause glucosuria and natriuresis as a result of competitive blockade 
of the SGLT2 protein. (Figure 11)  Canagliflozin was the first SGLT2-inhibitor 
to be approved for use in T2DM by the FDA in 2013, followed by dapagliflozin 






Figure 11. Mechanism of action of SGLT2-inhbitors on nephron(1)  
Reproduced with thanks to Parven Kaur 
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SGLT2-inhibitors result in a glycosuric effect of approximately 60-90 g/day in 
individuals with normal renal function.(114) Each agent has its own kinetics 
and has unique selectivity to different SGLT isoforms. (Figure 12)  For 
instance, empagliflozin is most selective toward SGLT2s, while canagliflozin 
is the least selective, and has a modest SGLT1-inhibiting effect in the distal 
PCT and intestines.(123) This raises interesting questions, for instance could 
canagliflozin be used in more obese patients with poorer glycaemic control as 
it is able to block intestinal uptake of glucose and augment the glycosuric effect 
by blocking distal PCT reabsorption of glucose (which is enhanced due to 
increased glucose delivery from the inhibition of the more proximal SGLT2s)? 
These questions will still need to be studied, particularly the potential off-target 
effects of blocking SGLT1 which is more widely distributed than SGLT2.  
10mg of Dapagliflozin, the drug used in the REFORM trial, has an oral 
bioavailability of 78% and its pharmacokinetics is unaffected by age, gender, 
ethnicity, weight and food consumption.(114) Other pharmacokinetic features 
have been summarised in Figure 12. As dapagliflozin is predominantly 
excreted by the kidneys, worsening renal function increased drug 
concentrations, in severe cases, by up to 80%. However, there was reducing 
efficacy with regard to its glucose-lowering effects with declining renal 
function.(114) Mild to moderate liver impairment does not affect dapagliflozin’s 






Figure 12. Pharmacokinetics of various SGLT2-inhibitors.(114) 
An important pharmacodynamic feature of SGLT2-inhibitors is the very low 
hypoglycaemia risk. This is due to two inherent ‘safety features’ of SGLT2-
inhibition. Firstly, by selectively blocking SGLT2 transporters that happen to 
be located in the proximal part of the PCT, there is increased glucose delivery 
downstream, resulting in increased glucose uptake by SGLT1 transporters 
located in the distal part of the PCT. Work on genetic knockout mice and 
human embryonic kidney cells show this increased glucose load to the distal 
PCT unmasks the transport capacity of SGLT1 and fully accounts for the 
residual glucose uptake in SGLT2-inhibition.(125,126) This essentially means 
that the effect of SGLT2-inhibition is cancelled out by increased SGLT1 activity 
once the glomerular-filtered load of glucose reaches approximately <80g /day. 
The second failsafe mechanism comes from metabolic counter regulation. 
Unlike other anti-diabetic agents that act directly on the insulin/incretin 
pathway, this metabolic pathway is unaffected by SGLT2-inhibition.  As will be 
discussed in chapter 1.6.5, SGLT2-inhibitors result in reduced insulin section 
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and increased plasma glucagon levels (resulting in hepatic gluconeogenesis) 
as well as shifting substrate utilisation away from carbohydrates toward lipid 
metabolism. These shifts in metabolism inherently prevent blood glucose 
levels from falling too low. These characteristics in the pharmacodynamics of 
this drug class has meant that hypoglycaemia has only been reported when 
SGLT2-inihbitors were used in combination with other anti-diabetic drugs, but 
not as monotherapy.(127)   
Another unique feature of SGLT2-inhibitors is their insulin-independent 
activity. Unlike other anti-diabetic agents that act either by increasing 
sensitivity to insulin or by manipulating the incretin pathway to increase insulin 
secretion, SGLT2-inhibitors act by a completely distinct mechanism that is 
unaffected by insulin levels or sensitivity. This allows the efficacy of SGLT2-
inhibitors to remain unchanged with progressive beta-cell dysfunction or 
worsening insulin resistance which is typical of T2DM. This also means that 
SGLT2-inhibitors can be used as synergetic agents to other glucose lowering 
drugs as they act on a different pathway.(116,128) There are authors that 
argue this insulin-independent activity combined with the insulin-lowering 
effects (through sustained glycosuria) of SGLT2-inhibitors allow them to 
preserve pancreatic beta-cell function, thereby delaying the progression of 
T2DM, although this will need further confirmation.(129)  
   
66 
 
1.6 CARDIO-METABOLIC EFFECTS OF SGLT2-INHIBITION 
1.6.1 Improved glycaemic control 
SGLT2-inhibitors have been shown to reduce HbA1c levels between 0.4% to 
1.1% depending on baseline HbA1c and type of SGLT2-inhibitor used. 
Canagliflozin which also has modest SGLT1-inhibitory activity, seems to have 
a slight advantage over the other agents.(130-132) 10 mg once daily of 
dapagliflozin reduces HbA1c between 0.58% to 1.11% in patients with 
T2DM.(133)  
Compared to other anti-diabetic agents, SGLT2-inhibitors seem to either be 
as effective or marginally superior in reducing HbA1c but are associated with 
lower risk of hypoglycaemia. When empagliflozin was compared to the 
sulfonylurea glimepiride as add on therapy to metformin, there was a more 
prominent HbA1c reduction with glimepiride initially, but at the end of the 2-
year observation period patients in the empagliflozin group saw an adjusted 
mean difference in HbA1c of -0.11% (95% CI -0.19 to -0.02; p=0.0153 for 
superiority) compared to the glimepiride group. Incidence of confirmed 
hypoglycaemia was 2% in the empagliflozin group vs 24% in the glimepiride 
group over the same duration.(134) In a meta-analysis of 25 trials involving 
nearly 15,000 patients Wang et al. showed that SGLT2-inhibitors were 
superior to DPPIV-inhibitors as monotherapy or add-on to metformin therapy 
in patients with T2DM. They found a weighted mean difference in HbA1c of 
0.13% (95% credible interval, 0.04%-0.22%, P = 0.005) in favour of SGLT2-
inhibitors, and no significant difference in hypoglycaemic events.(135) A real-
world observation of 411 patients receiving add on SGLT2-inhibitor to insulin 
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due to poor glycaemic control found patients on >200 IU/day insulin had a 23 
IU/day reduction with canagliflozin and 71 IU/day reduction with dapagliflozin 




1.6.2 Weight reduction 
A meta-analysis of 39 trials involving 25,000 individuals showed canagliflozin 
300mg, empagliflozin 25mg and dapagliflozin 10mg all at a once daily dosing 
resulted in a weight loss of 2.66kg, 1.80kg and 1.81kg respectively compared 
to placebo.(137)  
Early hypotheses suggested that the weight loss observed in the use of 
SGLT2-inhbitors were solely due to the loss of calories from glycosuria. 
However, there was a consistent underestimation of weight loss from the 
measured amount of calorific loss. In an edifying study, Ferrannini and 
colleagues demonstrated that the glycosuria induced an adaptive increase in 
calorie intake, accounting for the deficit between the expected and observed 
weight loss.(138)  
Certainly, in the initial stages of SGLT2-inhibitor therapy, caloric loss from 
glycosuria and fluid loss from osmotic diuresis are the two primary contributors 
to weight loss. However, these effects are transient and are usually lost 
beyond first 12 weeks, likely due to compensatory mechanisms.(139) 
More sustained weight loss in SGLT2-inhibitor therapy is due to fat loss. As 
will be discussed in the subsequent section, SGLT2-inhibitors induce lipolysis 
due to alterations in the insulin-glucagon ratio. Studies utilising dual-energy x-
ray absorptiometry (DEXA) have shown approximately 70% of the sustained 
weight loss in individuals with T2DM treated with dapagliflozin over 2 years 
was attributable to loss of body fat. An MRI sub-study revealed that there were 
numerically greater reductions in visceral adipose tissue compared to 
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subcutaneous adipose tissue in the dapagliflozin group.(140) This is 
potentially important because visceral adipose tissue has been implicated in a 
number of diseases including IHD, hypertension, T2DM and insulin resistance, 




1.6.3 Natriuresis and diuresis   
Inhibition of SGLT2 transporters in the proximal convoluted tubules results in 
glycosuria and natriuresis which, in turn, causes osmotic diuresis. This 
natriuretic and diuretic effect of SGLT2-inhibiton has been clearly 
documented.(142) An increase of mean urine volume of between 100-500 
mls/day has been reported in various phase 3 trials.(143)   
This effect is the putative mechanism of CV benefit by way of volume reduction 
resulting in lower BP, reduced pre- and afterload on the heart and 
decongestion in the case of HF.(144) Interestingly, SGLT2-inhibitors may have 
unique abilities over and above classical agents such as thiazide and loop 
diuretics. In a small study comparing dapagliflozin and hydrochlorothiazide, a 
7% volume contraction and 2.2 percentage-points increase in haematocrit was 
seen with dapagliflozin over a 12-week period. However, the 
hydrochlorothiazide group had significantly lower 24-hrs mean BP which was 
not seen in the dapagliflozin group.(145)  In a different mathematical modelling 
study, the authors found dapagliflozin to be far more efficient at removing 
interstitial fluid volume without compromising intravascular volume. The 
authors calculated that SGLT2-inhibitors can achieve this effect by promoting 
greater electrolyte-free water clearance compared to bumetanide, and in doing 
so, achieve a 200% reduction in interstitial volume compared to blood volume 
while bumetanide was only able to achieve 78% reduction in interstitial fluid 
compared to blood volume. This differential effect on volume regulation could 
be a game-changer in patients with HF who are frequently grossly volume 
71 
 
overloaded in the interstitium while simultaneously being intravascularly 
depleted (with low blood pressure and reduced cardiac output).(146)  
Finally, another unique feature of SGLT2-inhibitior-related diuresis is that there 
is no reflex sympathetic activation as is usually seen with the other diuretic 
drug classes.(147) Investigators have yet to fully clarify why this the case, but 
one could imagine the above discussion around the preserved intravascular 
volumes may be a potential explanation. Some authors have also speculated 
that this is an indirect effect of increased sodium delivery to the macula densa 
which is a specialised sodium sensor at the junction between the loop of Henle 
and distal convoluted tubule, forming part of the juxtaglomerular apparatus. 
The rise in tubular sodium concentration (as a result of SGLT2-inhibition) 
triggers a tubuloglomerular feedback mechanism that increases afferent 
arteriolar vasoconstriction to reduce renal blood flow into the glomerulus and 
reduces renin release (thus indirectly blunting sympathetic outflow) because 
of the ‘perceived’ high blood sodium levels as measured by the filtered sodium 
concentration within the tubules.(148) 
This is an important feature of SGLT2-inhibition as sympathetic overactivity 
has been associated with higher mortality in patients with HF(149) and this 
could perhaps be part of the explanation why diuretics have not been shown 




1.6.4 Blood pressure reduction  
SGLT2-inhibitors also reduce systolic and diastolic BP. A meta-analysis of 43 
trials that reported BP change involving 22,000 patients showed SGLT2-
inhibitors reduced the weighted mean systolic BP by -2.46 mmHg (95% CI -
2.86 to -2.06) and weighted mean diastolic pressure was reduced by -1.46 mm 
Hg (95% CI -1.82 to -1.09). The majority of the trials (n=23) had a duration of 
between 12-24 weeks. Interestingly, empagliflozin was most potent for systolic 
BP reduction (−2.59 mm Hg [95% CI −2.70 to −2.49]), while canagliflozin 
reduced diastolic BP the most (−2.23 mm Hg [95% CI −2.30 to −2.16]).(150) 
In another meta-analysis looking at 24-hours ambulatory BP, SGLT2-inhibitors 
were found to reduce systolic and diastolic BP by −3.76 mm Hg (95% CI, −4.23 
to −2.34) and −1.83 mm Hg (95% CI, −2.35 to −1.31), respectively. 
Dapagliflozin performed best in 24-hour mean systolic BP reduction (-3.73 
mmHg [95% CI -6.38 to -1.07]), while empagliflozin reduced 24-hour mean 
diastolic BP the most (-1.51 mmHg [95% CI -2.91 to -0.11]). (151) 
Importantly, this blood pressure lowering effect is independent of glycaemia; it 
has been observed in healthy individuals without T2DM (systolic BP reduction 
~ 2.7mmHg) (152) as well as in patients with moderate renal dysfunction, 
despite minimal reduction in HbA1c on SGLT2-inhibitor therapy.(143,152)  
The proposed mechanisms of BP reduction are threefold; firstly, plasma 
volume contraction from osmotic diuresis and natriuresis. Secondly by 
improved vascular physiology by way of reduced smooth muscle tone (through 
voltage-gated potassium (Kv) channels and protein kinase G activation), 
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reduced arterial stiffness and improved endothelial function. Thirdly, as an 




1.6.5 Lipolysis and increased ketone body production   
The proximal convoluted tubules of the renal nephron contain the highest 
concentration of SGLT2 transporters in the body, however SGLT2 transporters 
can also be found in numerous other organs such as the pancreatic alpha cells 
(but not in the beta cells)(155), testes, prostate, heart and brain.(112)   
In the pancreas the SGLT2 transporter is responsible for glucose uptake into 
the alpha cells which produces glucagon. When the SGLT2 transporters of the 
alpha cells are inhibited, it mimics a hypoglycaemic state and induces 
glucagon secretion via KATP channel activation and membrane 
repolarisation.(155) Simultaneously, as discussed in section 1.6.1 above, the 
glycosuric effect of SGLT2-inhibition in the kidney lowers blood glucose levels 
thereby reducing insulin production / requirements. This combination of lower 
insulin and higher glucagon levels shifts metabolism towards increased 
lipolysis and mild ketogenesis.(156)  This is the same triggering mechanism 
for diabetic ketoacidosis; the difference being in that case the reduction in the 
insulin : glucagon ratio is very large and rapid (occurring over hours to days) 
compared to SGLT2-inhibition where it is of a smaller magnitude and more 
protracted (occurring over weeks), resulting in a gradual and modest rise in 
ketone bodies. 
This effect of increased lipolysis and a modest rise in ketone bodies have 
beneficial effects by way of weight loss and improved myocardial energetics. 




1.6.6 Increased haemoglobin and haematocrit  
SGLT2-inhibitors increase haemoglobin (Hb) and haematocrit (Hct).(157) The 
early explanation for this was that of haemoconcentration from diuresis, 
however this was disproved when a discordance between Hct and serum 
osmolality was observed.(158)  Further work into this revealed on top of some 
haemoconcentration from diuresis, there is an increase in erythropoietin (EPO) 
production in patients on SGLT2-inhibitors. A 12-week study comparing 
dapagliflozin with hydrochlorothiazide and placebo showed increased red cell 
mass and EPO production,(145) while another using empagliflozin for 4 weeks 
showed a 60% increase in EPO production.(159) 
The mechanism behind this effect was explained by Sano and colleagues; The 
increased glucose load in renal tubules as a result of T2DM causes an 
upregulation of SGLT2 transporter activity in the renal cortex. This increases 
the cortical oxygen demand (as tubular glucose reabsorption is an active 
process), generating relative cortical ischaemia. EPO-producing fibroblasts, 
usually found in the renal cortex, respond to this ischaemia by transforming 
into (non-EPO producing) myofibroblast that promote interstitial fibrosis and 
predispose to renal dysfunction. When an SGLT2-inhibitor reduces renal 
cortical energy requirements by effectively shutting down these transporters, 
the myofibroblasts revert back to their original state resulting in increased EPO 
levels.(157,160)  
This increase in Hb / Hct is significant because it increases myocardial oxygen 
delivery and potentially plays a role in improving overall myocardial energetics 
(see sections 1.3.2 and 4.4). Indeed, a mediation analysis of the EMPA-REG 
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OUTCOME trial showed that 52% of the beneficial effect of empagliflozin on 
CV mortality can be attributed to its effect on haematocrit alone.(161)   
Nevertheless, this effect may also be a double-edged sword as there have 
been concerns around increased amputations (especially with the use of 
canagliflozin) and the lack of stroke protection, in spite of its glowing 
performance in CV risk reduction. Although a causal link has yet to be 




1.7 CARDIOVASCULAR OUTCOME TRIALS   
1.7.1 Overview  
At time of writing, there have been three large CV outcome trials studying each 
of the most widely available agents in the SGLT2-inhibitor class. By order of 
publication, they are the Empagliflozin Cardiovascular Outcome Event Trial in 
Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME), Canagliflozin 
Cardiovascular Assessment Study (CANVAS) and the Multicentre Trial to 
Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events 
(DECLARE-TIMI 58). There has also been a meta-analysis of all three trials 
providing a comprehensive overview of the CV protective effects of this drug 
class.  
In this chapter we briefly discuss the key features of each of these trials to form 
an understanding of the potential effects of this drug class on CV outcomes. 
Even though the REFORM trial was conceived before any of these trials 
published their findings, many of the results from our work supplements and 





1.7.2 EMPA-REG OUTCOME 
The EMPA-REG OUTCOME trial (162) published in 2015 studied 7000 
individuals with T2DM over a mean follow up period of 3 years. Patients were 
randomised to either empagliflozin 10mg OD, 25mg OD or placebo in equal 
proportions.  
This was the only trial, of the three, that mandated established CV disease 
(defined as previous MI / stroke, confirmed coronary or peripheral arterial 
disease of >50% occlusion) along with T2DM as the inclusion criteria. This 
meant that the EMPA-REG cohort had the highest risk profile of the three 
SGLT2-inhibitor CV outcome trials.  
The average age was 63 years, majority white male population with nearly 
60% having T2DM for at least 10 years. Approximately ¾ of patients had 
coronary artery disease, and approximately 20% each with stroke and 
peripheral arterial disease. Only 10% had a prior diagnosis of HF, but it is 
important to note that this classification was simply made by asking trial 
patients if they had a diagnosis of HF and no formal confirmation (e.g. by 
measuring natriuretic peptides or performing an echocardiogram) was 
required. Majority of patients were on ACE-i/ARB (81%) and beta-blockers 
(65%). Interestingly 44% were on diuretic therapy suggesting that, perhaps, 
there were more patients with HF in the trial. 
Pooled analysis (both arms of empagliflozin together vs placebo) showed 
relative risk reduction in MACE (CV death, nonfatal MI / stroke) by 14%; HR 
0.86; (95% CI 0.74-0.99); p=0.04. Rather unexpectedly there were also striking 
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reductions in all-cause mortality (HR 0.68; 95% CI 0.57-0.82; P<0.001), CV 
mortality (HR 0.62; 95% CI 0.49-0.77; P<0.001) and HF hospitalisation (HR 
0.65; 95% CI 0.50-0.85; P=0.002) There was an overall 5/2 mmHg blood 
pressure reduction and an approximately 2kg weight loss in the empagliflozin 
arm.(163) 




The CANVAS trial (164) was published in 2017. It recruited around 10,000 
individuals with T2DM and followed them for an average of nearly 4 years. 
Patients were randomised to either canagliflozin 100mg OD, 300mg OD or 
placebo in a 1:1:1 fashion.  
CANVAS allowed both established and at-risk CV disease individuals to be 
recruited. An individual was considered at risk for CV disease if they had 2 or 
more of the following: long-standing T2DM (≥10 years), poorly controlled BP 
while on at least 1 BP-lowering agent, cigarette smoker, documented 
micro/macro -albuminuria or documented HDL <1mmol/l.  
The average age was 63 years, majority white male population with an 
average duration of T2DM of 13.5 years. Approximately 60% of the cohort had 
established CV disease, while the remainder were at-risk of CV disease. Once 
again, only a small proportion (14%) had a prior diagnosis of HF. In spite of 
the lower risk profile, the baseline medications of ACE/ARB (80%), beta-
blockers (54%) and diuretics (44%) were similar to EMPA-REG OUTCOME.  
Pooled analysis showed lower MACE (HR 0.86; 95% CI, 0.75 to 0.97; p=0.02) 
and lower HF hospitalisation (HR 0.67; 95% CI, 0.52 to 0.87) which are 
comparable to the findings of EMPA-REG OUTCOME. There was no 
significant reduction in mortality.  
The mean difference in body weight was –1.60 kg (95% CI, –1.70 to –1.51), 
while difference in systolic blood pressure was –3.93 mm Hg (95% CI, –4.30 
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to –3.56), and diastolic blood pressure was –1.39 mm Hg (95% CI, –1.61 to –
1.17). There was less progression to albuminuria and amongst those already 
with albuminuria, they were more likely to regress; 0.73 (95% CI, 0.67 to 0.79) 
and 1.70; (95% CI, 1.51 to 1.91) respectively. Importantly, there was also 40% 
less need for renal-replacement therapy, or death from renal causes in the 
canagliflozin group; 0.60; (95% CI, 0.47 to 0.77).  
There were some potential safety concerns raised in the CANVAS trial, other 
than the commonly accepted genital infection and euglycaemic ketoacidosis. 
There was a higher risk of amputation; 1.97; (95% CI, 1.41 to 2.75) and 
patients with the highest risk for amputation were those with a previous 
history of amputations or documented peripheral vascular disease. More 
fractures were also noted in the canagliflozin group; 1.26; (95% CI, 1.04 to 
1.52). It is still unclear if this is a class effect or a problem specific to 
canagliflozin as it was not seen in trials for other members of the class.  
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1.7.4 DECLARE-TIMI 58  
The most recent study to be published is the DECLARE - TIMI 58 trial.(165) It 
randomised 17,000 patients with T2DM to dapagliflozin 10mg OD vs placebo 
and followed them for a median of just over 4 years. 
The average age was 64 years, majority white men with a median duration of 
T2DM of 10.5 years. In contrast to CANVAS, 60% of the cohort were at risk of 
developing CV disease while the remaining had established disease, the 
majority of which (33%) was that of coronary artery disease. Only 10% had a 
diagnosis of HF. Once again, baseline medications were comparable to the 
other trials with 81% on an ACE-I / ARB, 52% on beta-blockers and 41% on 
diuretics even though this was a much lower risk group.  
Dapagliflozin had no effect on MACE (HR 0.93; 95% CI 0.84 - 1.03; p = 0.17) 
or CV death (HR 0.98; 95% CI 0.82 - 1.17). However, there were significantly 
lower hospitalisations for HF (HR 0.73; 95% CI 0.61 - 0.88). In this study as 
well, investigators noted a reduction in mean weight by 1.8 kg (95% CI 1.7 - 
2.0), systolic BP by 2.7 mmHg (95% CI, 2.4 - 3.0), and diastolic BP by 0.7 
mmHg (95% CI, 0.6 to 0.9). 
A recently published subgroup analysis of the DECLARE TIMI-58 trial(166) 
showed that dapagliflozin reduced CV death and all-cause mortality in patients 
with HFrEF (defined as a previously a documented LVEF of <45%) - HR 0.55, 
95% CI 0.34 - 0.90; pinteraction=0.012 and HR 0.59, 95% CI 0.40 - 0.88: 
pinteraction=0.016 respectively. This was the first time the effects of an SGLT2-
inhibitor were stratified by severity of LV dysfunction (as defined by LVEF).  
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There is a clear pattern emerging from these three trials; as the risk profile of 
their cohorts increase, so does the ‘efficacy’ of SGLT2-inhibition in reducing 
mortality (CV death) and morbidity (MACE). However, the reduction in HF 
hospitalisation remains robust and very consistent across the spectrum. Of 
course, this could also be a differential effect between the various agents in 
the class, but this is difficult to ascertain from current data. Another consistent 
feature of all the trials was that of weight loss and BP reduction.     
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1.7.5 SGLT2-Inhibitor CV Outcomes Meta-Analysis  
Shortly after the completion of DECLARE-TIMI 58, a meta-analysis reviewing 
all three trials was published.(167) 
A total of 34,000 individuals were included in the work, in which 60% had 
established CV disease and 11% with a diagnosis of HF. There was an overall 
11% reduction in MACE (HR 0.89; 95% CI 0.83–0.96, p=0.0014) but subgroup 
analysis showed this was restricted to those with established CV disease 
where a 14% reduction in MACE was seen compared to no change (0%) in 
those with CV risk only. There was a 23% reduction in the composite of CV 
death and HF hospitalisation (HR 0.77; 95% CI 0.71–0.84, p<0.0001), which 
was seen equally, with or without CV disease and with or without HF. The 
benefits of HF hospitalisation remained robust throughout all subgroups of CV 
risk / disease / HF. However, there seemed to be a greater benefit in patients 
with more severe renal function - eGFR < 60 mls/min/1.73m2 (HR 0.60 95% 
CI 0.47–0.77, p<0.0001) and eGFR 60-90 mls/min/1.73m2 (HR 0.69; 95% CI 
0.57–0.83, p<0.0001) - compared to those with normal renal function (HR 0.88; 
95% CI: 0.68–1.13, p=0.31). Strikingly, there was a 45% reduction in the 
progression of renal disease (HR 0.55; 95% CI 0.48–0.64, p<0.0001) which 
was maintained regardless of CV history. (Progression of renal disease was 
defined differently between trials; all trials used a composite of three 
measures, namely, initiation of renal replacement therapy or death from renal 
causes or worsening renal function. The difference was in the definition of 
worsening renal function; defined as doubling of serum creatinine in EMPA-
REG OUTCOME, 40% reduction in eGFR (based on Modification of Diet in 
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Renal Disease equation) in CANVAS and 40% reduction in eGFR (based on 
the Chronic Kidney Disease Epidemiology Collaboration equation) in 
DECLARE TIMI-58)   
There was no signal of increased risk of stroke and the increased risk of 
amputations and fractures were only seen with the use of canagliflozin 
(recognising that this study only involved 1 trial for each drug in class, which 
is far from conclusive). There was a clear increase in mycotic genital infections, 
but these were easily treated, and recurrence was uncommon. The risk of 
diabetic ketoacidosis (not specified whether this was euglycemic ketoacidosis) 
was doubled in the SGLT2-inhibitor group compared to placebo but the 
absolute incidence remained very low at <0.1%.  
This meta-analysis shows that SGLT2-inhibitors have primary preventive 
effects with regard to renal protection and prevention of HF hospitalisation but 
reduction in MACE is only seen in established CV disease. Nevertheless, it is 
important to recognise that T2DM itself significantly increases risk of 
renovascular disease and HF, therefore any protection conferred by SGLT2-
inhibitor therapy regardless of the ‘conceptual’ distinction of primary or 
secondary prevention cannot be underestimated. This was supported by the 
recent joint consensus report by the American Diabetes Association (ADA) 
and European Association for the Study of Diabetes (EASD) recommending 
that after initiating metformin, SGLT2-inhibitor therapy should be first choice 
for all patients with T2DM and HF or renal disease and joint first choice with 
GLP-1 receptor agonists for patients with atherosclerotic CV disease.(168)  
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1.8 RESEARCH HYPOTHESIS 
We aimed to test if the various unique characteristics of SGLT2-inhibiton are 
beneficial in HF by either favourably remodelling the LV and / or improving 
exercise capacity in patients with T2DM and HF.  If so, it would strengthen the 
case for early initiation of SGLT2-inhibitors in this cohort. (The recent ADA / 
EASD recommendations had not been published at the time of conception of 
this trial) 
The main premise behind this hypothesis is that SGLT2-inhibitors are mild 
diuretics which should reduce LV preload and LV end diastolic / systolic 
volumes, thereby resulting in LV reverse remodelling. Whether this diuretic 
effect will actually occur in HF where eGFR are at the lower end of normal (or 
mildly impaired) plus the concomitant use of chronic loop diuretic therapy, is 
not yet known.  Secondly, SGLT2-inhibitors reduce BP which should reduce 
LV afterload and further contribute to LV reverse remodelling.  
A beneficial effect on LV remodelling in HF has major implications on mortality 
in HF patients with T2DM as it is the best surrogate for disease progression 
and survival in patients with HF. Indeed, in 2000 the International Forum on 
Cardiac Remodelling published a consensus document stating that new drug 
treatments in HF should be assessed by their effect on LV remodelling.(169)  
Serial changes in LV remodelling parameters are an excellent way to assess 
the effect of therapeutic interventions (drugs or devices) on clinical outcomes 
in patients with left ventricular systolic dysfunction (LVSD).(170) Kramer et 
al(171) confirmed this when they meta-analysed 30 mortality trials (involving 
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25 drugs or device interventions) and 88 remodelling studies, showing 
excellent correlations between effects on LV remodelling and mortality.  The 
odds ratio for death in the mortality trials was correlated with drug/device 
effects on changes in LVEF (r=-0·51, p<0·001), LV EDV (r = 0.44, p = 0.002) 
and LV ESV (r=0·48, p=0·002). Thus, if SGLT2-inhibitors did result in LV 
reverse remodelling in HF patients with T2DM, this could provide a 
mechanistic explanation for the mortality benefits seen in the large SGLT2-
inhibiotor CV outcome trials.  
SGLT2 inhibitors may also improve exercise tolerance, a universal symptom 
of patients with HF. Firstly, SGLT2 inhibitors have been shown to cause weight 
loss which will improve exercise effort. Secondly, SGLT2 inhibitors may 
improve exercise capacity by improving insulin sensitivity. Better insulin 
sensitivity has been shown to improve exercise capacity in diabetic individuals 
(172)  and in patients with HF.(173) SGLT2 inhibitors have been shown to 
improve insulin sensitivity in Zucker diabetic fatty rats treated with 
dapagliflozin(174) and empagliflozin(175). In a randomized, double blind 
placebo controlled study, dapagliflozin treatment improved insulin sensitivity 
as measured by glucose disappearance rate during hyperinsulinaemic 
euglycaemic clamping in T2DM patients.(176)  Thus, there is a potential that 
SGLT2-inhibitors, by causing weight loss and improving insulin sensitivity, may 
improve exercise capacity in patients with HF. 
In summary, we hypothesize that the unique effects of SGLT2-inhibition may 
result in improved haemodynamics (by way of reduced preload, afterload and 
BP) and metabolic function (by way of improved insulin sensitivity and weight 
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loss) resulting in LV reverse remodelling and improved exercise capacity 
which are central facets of improving morbidity and mortality in HF. At the time 
this study was conceived there were no data on HF (or even CV) outcomes 
related to the use of SGLT2-inhibitors. However, as the large SGLT2-inhibitor 
CV outcome trials started reporting an unexpected but striking benefit in HF 
hospitalisation and mortality, we recognised that this work could provide 
important mechanistic insights into those findings. This was of particular 
importance because only a small proportion of the patients of those trials 
(10.0% to 14.4%) actually had a diagnosis of HF,(162,164,165) making it 
difficult to fully appreciate its effects in this cohort of patients, necessitating a 







2.1 FUNDING, APPROVALS AND TRIAL REGISTRATION   
 
Funding:  
The REFORM trial was funded by the European Foundation for the Study of 
Diabetes (EFSD) as part of their Clinical Diabetes Research Programme 
supported by an unrestricted grant from Astra Zeneca / Bristol-Myers Squibb.  
 
Ethical Approval:  
The REFORM trial was approved by the East of Scotland Research Ethics 
Committee on 19th August 2014. Reference number 14/ES/1050.  
 
Medicines and Healthcare products Regulatory Agency (MHRA) 
Approval:  
The REFORM trial was approved by the MHRA on 23rd December 2014 with 





Trial Registration:  
The REFORM trial was registered with the U.S. National Institutes of Health 
via the U.S. National Library of Medicine website Clinical Trials.gov with the 
identification number NCT02397421. The trial was also registered with the UK 
Clinical Research Network with the identification number 18467.  
 
Local approval:  
The REFORM trial received final approval from the NHS Tayside Research 
and Development Committee on 13th February 2015 with an overall greenlight 
to start recruitment on 5th March 2015.   
91 
 
2.2 STUDY DESIGN  
The REFORM trial was a single centre, double blind, placebo-controlled, 
parallel arms clinical trial. Patients were randomised in a 1:1 ratio to either 
10mg dapagliflozin once daily or placebo (microcrystalline cellulose Ph Eur 
over encapsulated in a hard gelatine capsule shell). They were then observed 
for 1 year with between 8 to 9 visits, three of which were telephone ‘visits’. 
Details of the visit schedule and tests performed during these visits are 
discussed in section 2.8.  
 
2.3 INCLUSION /EXCLUSION CRITERIA 
Patients were eligible if they were:  
•  Aged between 18 years to 75 years with previously diagnosed T2DM 
•  Diagnosed with NYHA functional class I-III HF with prior echocardiographic 
evidence of LVSD (Calculated LVEF of <45% or at least mild LVSD on 
subjective ‘eyeballing’ assessment)   
•  On furosemide 80mg daily or less, or equivalent loop diuretic 
•  Have stable HF symptoms for at least three months prior to consent 
•  On stable therapy for HF for at least three months prior to consent 
•  Have not been hospitalised for HF for at least three months prior to consent 
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Patients were excluded for the following: 
• screening HbA1c <6.0% 
 severe hepatic disease 
• renal disease defined as CKD stage 3B or worse (i.e. eGFR or CrCl 
<45ml/min) 
• systolic BP <95mmHg at screening visit  
• unable to walk to perform cardio pulmonary exercise testing or 6MWT 
• malignancy (receiving active treatment) or other life-threatening diseases 
• pregnant or lactating women 
• any contraindication to CMR (e.g. claustrophobia, metal implants, penetrative 
eye injury or exposure to metal fragments in eye requiring medical attention) 
• patients who have participated in any other clinical trial of an investigational 
medicinal product within the previous 30 days 




2.4 COHORT SIZE AND POWER CALCULATIONS  
Improvement in LV volumes have been shown to be an important marker for 
the efficacy of a drug / device therapy on improving heart failure survival.(170) 
Grothues et al. suggest a 10 mL change in LVEDV and LVESV as clinically 
significant and have reported the SD for the mean difference of LVEDV and 
LVESV as 7.6 and 7.4 respectively.(177) Therefore, to detect a 10 mL change 
in LVEDV and LVESV (primary endpoint) with 90 % power and α error (p value) 
of 0.05, a sample size of 13 and 12 respectively were required per arm.  
LV mass is also an important determinant of survival in patients with HF and a 
10 g reduction in LV mass has been shown to be clinically 
meaningful.(170,177) The reported SD for 10 g mean change in LV mass in 
the HF population is 9.6 using CMR, implying 20 patients were required per 
arm.(177) 
Kramer et al demonstrated the change in LV EF which best discriminated 
between drugs with positive and neutral effects on mortality was 3%. This 
degree of improvement in LV EF was also associated with a 20% improvement 
in mortality.(171) This is echoed by Grothues et al who recommend this 
magnitude of change be used to power studies. Our previous CMR experience 
has shown an in-house and published SD of the change in LV EF within 
individuals over time as 3.75% for both active and placebo therapies.(178) 
Therefore in order to have 80 % power at p < 0.05 to detect a ≥3% change in 
LVEF in a parallel group study, 26 patients per group were needed.  
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As this was a discovery trial, we aimed to ensure the trial was adequately 
powered to detect all the clinically relevant markers of LV remodelling (LV 
volumes, mass and EF). Therefore, we aimed to recruit a minimum of 52 
patients (26 patients per arm) to provide at least 80 % power (α error of 0.05) 






2.5 INFORMED CONSENT AND RECRUITMENT  
Majority of patients were recruited from the Tayside area. We accessed the 
Tayside pool of the Systems Biology Study to Tailored Treatment in Chronic 
Heart Failure (BIOSTAT) database consisting of around 1800 patients with HF 
who had previously consented to be approached for future research. We also 
identified patients from the Scottish Primary Care Research Network 
(SPCRN), The Scottish Health Research Register (SHARE), Generation 
Scotland Database, Scottish Diabetes Research Network and Wellcome Study 
Database. Besides identifying potential patients from various databases, we 
also performed opportunistic recruitment from cardiovascular and HF clinics 
as well as from the cardiac rehabilitation program conducted in Ninewells 
Hospital.  
All patients who were considered suitable for the trial were provided with a 
patient information leaflet (Appendix 9.1) at least 24 hours prior to giving 
informed consent. At the first visit they were counselled by the principal 
investigator before an informed consent was taken (Appendix 9.2).  
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2.6 RANDOMISATION  
After successful recruitment into the trial, patients were randomised to either 
dapagliflozin 10 mg or matching placebo in a double-blind fashion. The trial 
medication (dapagliflozin or placebo) was prepared, packaged and labelled by 
our onsite clinical trials pharmaceutical manufacturer. Randomisation was 
carried out by our dedicated clinical trials pharmacy using block randomisation. 
They used a validated randomisation program and securely backed-up both 
the randomisation seed and the treatment allocation. The allocation key was 
always available in the onsite 24-hour emergency unblinding facility in the 




2.7 STUDY VISITS 
At the screening visit an initial medical history and clinical examination was 
performed following informed consent. Patients had blood taken for safety 
analysis and vital signs recorded to confirm eligibility prior to enrolment. 
Patients who met the inclusion criteria and had no exclusions identified 
returned for a CMR scan at the Clinical Research Centre, Ninewells Hospital, 
Dundee within 4 weeks of the planned baseline (randomization) visit.  
At the randomization visit patients performed a six-minute walk test (6MWT), 
quality of life questionnaire, vital signs assessment, body composition analysis 
(BCA) and cardio-pulmonary exercise test (CPET) measurements taken. 
During this visit, patients were also randomly assigned to either dapagliflozin 
10 mg or matching placebo. The first dose was administered at this visit and 
patients were educated on the symptoms of hypoglycaemia and given a 
written action plan on how to manage it in the event it occurred. Patients on 
insulin had their total daily dose reduced by 10 % and given a 2-week glucose 
monitoring chart with written instructions to self-manage their insulin doses. 
(Appendix 9.3)  
Patients returned 2 weeks later for a short safety visit where safety blood 
investigations (eg full blood count, renal and hepatic function tests and NT-
proBNP) were performed, adverse events and vital signs were also monitored. 
Patients who were on insulin had their self-monitoring charts reviewed and 
further dose adjustments made if necessary.  
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This was followed by 2 more visits on months 2 and 6 with the same agenda. 
Three telephone visits were included in the trial follow-up schedule, at week 4, 
months 4 and 9. These telephone calls enabled the research team to follow 
up on changes in concomitant medications, adverse events and to remind the 
participant of study drug compliance. Compliance to study drug was 
determined by pill counting, carried out by the pharmacy team who report back 
to trial team after each returned batch. 
Trial patients continued all their usual medications, which remained 
unchanged throughout unless clinically indicated. If any titration of a 
participant’s other medications (eg anti-diabetic agents or diuretic agents) 
were indicated, changes were done in consultation with their general 
practitioners, and the changes recorded for analysis.  
At the end of the 1-year study period, patients returned for a repeat 
assessment of the 6MWT, quality of life measures, BCA, CPET and CMR. 
Table 6 shows a summary of all visits and procedures in tabular format.  
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2.8 PHARMACOVIGILANCE  
The REFORM trial was conducted in accordance to the Helsinki Declaration 
and the principles of Good Clinical Practice (GCP). The trial was monitored at 
regular intervals by the Tayside Clinical Trials Unit to ensure compliance to 
GCP.  
We ensured there was regular contact with all patients, at shorter intervals 
initially then gradually increased. At each visit the clinical trial team 
emphasized treatment compliance and enquired about any potential adverse 
event. If there was concern about a potential side effect or adverse event, 
(defined below) this was escalated to the principal investigator for further 
assessment. If an adverse event had occurred details of the event was 
recorded including date(s) of the event(s), causality, severity, action taken and 
date of resolution. If the event was deemed as a serious adverse event, it was 
reported to the Tayside Pharmacovigilance team within 24 hours.  
An adverse event (AE) is defined as any untoward medical event affecting a 
clinical trial participant. Each initial AE will be considered for severity, causality 
or expectedness and may be reclassified as a serious event or reaction based 
on prevailing circumstances. An adverse reaction (AR) is where it is suspected 




A serious adverse event (SAE), serious adverse reaction (SAR) or suspected 
unexpected serious adverse reaction (SUSAR) is any AE, AR or UAR that at 
any dose: 
 results in death 
 is life threatening 
 requires hospitalisation or prolongation of existing hospitalisation 
 results in persistent or significant disability or incapacity 
 is a congenital anomaly or birth defect 
 or is otherwise considered serious  
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2.9 OUTCOME MEASURES  
2.9.1  Cardiac Magnetic Resonance Imaging 
CMR was performed at randomisation and final visits only. Prior to each scan 
MRI safety was established for every patient by the principal investigator, then 
re-confirmed by the research imaging team just prior to the study as per the 
NHS Tayside Radiology Safety Procedures.  
All imaging was performed on a 3 Tesla Magnetom Trio/PrismaFIT (Siemens, 
Erlangen, Germany) scanner using body array cardiac and spine matrix 
radiofrequency coils. In brief, the examination consisted of localizer scans 
followed by retrospectively gated 2D CINE segmented true fast imaging with 
steady state precession sequences (TrueFISP) in the vertical long axis (2 
chamber) and horizontal long axis (4 chamber) orientations. This was followed 
by a stack of short axis plane acquisitions (using the same pulse sequence) 
acquired sequentially from the atrio-ventricular ring to the apex of the left 
ventricle.  Segmentation analysis of the LV images was performed by a single 
blinded observer (Dr. Ify Mordi) using Argus software on a multi-modality work 
platform (Siemens).  Contours were placed around the endocardial and 
epicardial borders of the LV myocardium on all short axis images acquired at 
end diastole and end systole.  Careful segmentation rules were followed where 





2.9.2  Safety blood tests 
All patients underwent a battery of routine blood investigations at every in-
person visit. These tests included a full blood count, urea and electrolytes, liver 
function test, HbA1c (except visit 3), fasting blood sugar and NT-proBNP. 
These investigations (except NT-proBNP – see below) were performed by the 
NHS Tayside Blood Sciences Department in Ninewells Hospital according to 
their established procedures and protocols. The results were reviewed by the 
principal investigator and any action that was required (e.g. dose reduction of 
loop diuretic due to renal impairment) was done in consultation with the 
patient’s GP.   
 
2.9.3 Cardiopulmonary exercise testing  
Patients performed a graded maximal bicycle exercise test with expired gas 
analysis using the Innocor System (Innocor, Innovision A/S, Odense, 
Denmark) which allows determination of peak VO  and other exercise 
parameters. The CPET was performed at randomisation and final visits only.  
Peak oxygen uptake was defined as the highest value of oxygen uptake 
achieved in the final 20 seconds of exercise. As many patients with HF are 
unable to perform maximal exercise, and oxygen requirements for daily 
activities rarely approach maximal levels, a submaximal derived exercise 
variable of the slope of the ratio of minute ventilation (VE) to carbon dioxide 
production (VE/VCO2 slope) was included in results and analysis.  
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Due to unavoidable work and time restrictions, the principal investigator was 
unable to conduct final-visit CPET tests for a number of patients. This task was 
delegated to trained research nurses who received individual direction and 
training on how to conduct a CPET from the principal investigator before being 
delegated to carry out the test. 
 
2.9.4  Six-minute walk test  
The 6MWT is a submaximal test of an individual’s functional status exercise 
capacity. Although correlation with NYHA classification and long-term risk 
stratification is poor,(179,180) it is an objective and simple tool to assess 
change in exercise capacity in HF.   
All patients underwent 6MWT testing at the beginning and end of the trial. The 
test was conducted on a flat surface with a 25-metere track marked along the 
laboratory corridor. They were briefed on how to perform the test and were not 
encouraged while performing the test by the person conducting the test. Vital 
signs including pulse oximetry were recorded prior to and just after completing 




2.9.5  Body composition analysis  
As SGLT2-inhibition results in both diuresis and weight loss, we were keen to 
identify the degree of change in total body water and overall fat composition 
using a simple and non-invasive method. Measuring the bioelectrical 
impedance allows the estimation of total body water and fat content based on 
the principle that electrical current flows easily in water (with electrolytes) and 
is resisted by fat tissue.(181)  
All patients underwent body composition analysis at every in-person visit using 
the TANITA BC-420-MA (Tanita Corp. Japan) machine. All patients removed 
their footwear (to allow direct contact with the footplates) and a standard 
clothes weight of 1 kg was automatically subtracted from their measured 
weight by the software in the machine. In the randomization and final visits, 
the measurements were taken before exercise tests were performed.  
 
2.9.6  Quality of life questionnaires 
Quality of life (QoL) questionnaires were conducted at the beginning and end 
of the study period. General and disease specific QoL measures were 
evaluated using the 36-item Short Form Survey (SF-36) and the Minnesota 
Living with Heart Failure (MLHF) questionnaires respectively.  
The SF-36 had 36 questions which were then scaled and scored to provide 
insight into eight health domains namely, physical functioning, bodily pain, role 
limitations due to physical health problems, role limitations due to personal or 
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emotional problems, emotional well-being, social functioning, energy/fatigue, 
and general health perceptions. Each domain has its own mean (norm) and 
ranges from 0 to 100 points, higher values indicating better outcomes.(182) 
These domains can be grouped into two larger clusters of the Physical 
Component Summary (PCS) and the Mental Component Summary (MCS). As 
QoL is a secondary outcome of the trial, we used the two broad clusters to 
measure QoL. The use of the SF-36 in patients with cardiovascular disease 
has been previously validated.(183) 
The MLHF questionnaire is one of the most widely used QoL questionnaires 
in patients with HF both in clinical practice and research.(184) It comprises 21 
questions on a six-point Likert scale. It provides an overall score ranging from 
0 to 105; with lower values indicating better QoL. Its use in the clinical and 
research context in patients with HF has been validated numerous 
times.(184,185) 
The SF-36 and MLHF questionnaires have been included in Appendices 9.4 




2.9.7  N-Terminal Pro B-type Natriuretic Peptide  
NT-proBNP has been validated and is recommended for the diagnosis of HF 
by international guideline committees.(23) It has also been suggested as a 
possible objective measure of longitudinal disease activity and been used in 
the follow-up of patients with chronic HF.(186)   
We measured NT-proBNP concentration at every in-person visit for two 
reasons; firstly, as a safety measure to ensure patients were not deteriorating 
and required urgent intervention, secondly as a secondary outcome measure 
to determine if the use of an SGLT2-inhibitor (and the potential improvement 
in LV remodelling) resulted in lower concentrations of NT-proBNP.  
Blood samples were collected by the principal investigator (or delegate) and 
spun immediately. Serum samples were then analysed by the University of 
Dundee Core Laboratory using multi array ELISA (Meso Scale Discovery, 




2.9.8  Beta-hydroxybutyrate  
Beta-hydroxybutyrate (BHB) is a ketone body. As discussed in detail in the 
previous section, SGLT2-inhibition shifts metabolism towards ketogenesis as 
a result of increased lipolysis and reduced insulin:glucagon ratio. This effect 
has been consistently documented in the T2DM population but not in the HF 
population till date. We also aimed to determine if an increase in BHB was 
associated with LV reverse remodelling as there have been suggestions that 
ketone bodies may be a more efficient fuel substrate for failing hearts.(62) 
Although only positron emission tomography or MRI-isotope tracer studies can 
conclusively determine changes in myocardial oxygen consumption and fuel 
energetics, we felt demonstrating a link between BHB and remodelling was an 
important hypothesis generating surrogate.  
BHB levels were measured at randomisation and final visits only. Blood 
samples were centrifuged and serum stored for later batch analysis at the end 
of the trial by the University of Dundee Core Laboratory using ELISA 




2.10 DATA ENTRY & MANAGEMENT  
Data were collected by the principal investigator or delegate identified in the 
delegation log with specific training in data collection. The data collected were 
initially noted on paper case report forms (CRF) which were stored in a secure 
filing cabinet in a locked room on site. Access to the CRF was only available 
to the principal investigator.  
The data were then transcribed into Microsoft Excel (Microsoft Corp. USA) by 
the principal investigator or delegate in batches. Each update of the main 
Excel database was saved as a new file with the date of data entry as part of 
the filename. The database (and all other trial-related data) was stored and 
encrypted on the University of Dundee’s cloud computing software 
collaboration with Box (Box Inc. USA). The data were backed up as per the 
university and Box Inc.’s policies. Once all data were collected, data 
verification and validation were performed by the principal investigator and the 
final database locked.  
MRI data were anonymised by the research imaging team and stored locally 
for interpretation and analysis. A blinded observer (Dr. Ify Mordi) then analysed 
the data on site and transcribed the relevant research findings on to a CMR-
outcomes database on Microsoft Excel. This database was then merged onto 
the main database just prior to data validation and database lock. All non-
anonymised CMR images were stored on NHS Tayside Picture Archiving and 
Communication Systems (PACS) that are accessible across Scotland. These 
images were reviewed by Professor Graeme Houston (or delegate) to confirm 
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that there were no clinically actionable findings and a blinded summary report 




2.11 STATISTICAL ANALYSIS  
2.11.1 General Considerations 
All continuous variables were summarised using the following descriptive 
statistics: n (non-missing sample size), number of missing records, mean, 
standard deviation, median, maximum and minimum. The frequency and 
percentages (based on the non-missing sample size) of observed levels were 
reported for all categorical measures. In general all data were listed, sorted by 
subject and treatment and where appropriate by visit number within subject. 
All summary tables were structured with a column for each treatment in the 
order and an additional column for the total population relevant to that 
table/treatment, including any missing observations. Student’s t test (or Mann-
Whitney test for non-parametric distributions) and Chi-squared for categorical 
variables was used to test statistical difference between groups at baseline. 
Primary analysis was performed on a per-protocol basis with sensitivity 
analysis on an intention to treat basis. Missing data were imputed using the 




2.11.2 Efficacy analysis  
Data for continuous outcome measures were assessed for normality prior to 
analysis. Transformations of the outcome variables were used where 
necessary if not normally distributed. 
If data were normally distributed, outcome measures were assessed by 
multivariable linear regression, controlling for baseline values, age, sex and 
renal function. Sensitivity analysis was also performed using models correcting 
for baseline NT-proBNP in view of the unexpected difference between groups 
at baseline. Categorical outcomes were analyzed using Pearson’s chi-square. 
Where data were not normally distributed and could not be transformed into a 
normal distribution, it was analysed using non-parametric methods in addition 
to multiple linear regression. 
Two patients were excluded from weight analysis; one in dapagliflozin arm had 
unexplained excessive weight gain of 9kg and one in placebo arm with 15.4kg 
weight loss following intensive gym program that was not informed to the 
research team. Both were large outliers. One patient, in the placebo arm, was 
excluded from all CMR-derived analysis because baseline CMR images were 




2.11.3 Safety analysis 
An all-participant analysis was performed for all safety variables. Adverse 
events (AE) were coded using the Medical Dictionary for Regulatory Activities 
(MedDRA)(Version 21.1 English September 2018) coding system. In cases 
with more than one diagnosis present in the AE description, the AE was split 
with all the descriptors kept the same for all diagnosis. Subjects were analysed 
for total number of events (including recurrences) for a particular type of AE. 
 
2.11.4 Technical details  
P-values that were more than 0.001 were reported to 3 decimal places, while 
p-values less than 0.001 were reported as “<0.001”. The mean, standard 
deviation, and any other statistics other than quantiles, were reported to one 
decimal place. Quantiles, such as median, or minimum and maximum used 
the same number of decimal places as the original data. Estimated 
parameters, not on the same scale as raw observations (e.g. regression 
coefficients) were reported to 2 decimal places. All analyses were performed 
using R version 3.4.3 for windows (R Foundation for Statistical 




 3. RESULTS  
3.1 STUDY RECRUITMENT 
Over a recruitment period between May 2015 and August 2016 a total of 85 
individuals were invited to participate in the trial. Sixty-two provided informed 
consent but only 56 were recruited as 3 individuals were unable to undergo 
CMR (1 historic metal eye injury and 2 with BMI>48kg/m2 which exceeded the 
limitations of the scanner), 2 individuals failed pre-randomization blood tests 
(eGFR <45ml/min/1.73m2), and 1 individual had severe aortic regurgitation 
requiring intervention. Approximately 10% more than the required 52 patients 
were recruited to allow for dropouts during the trial as we were studying a high-
risk population. (Figure 13) 
Of the 56 patients recruited, 28 were assigned to the dapagliflozin and placebo 
arms each. Seven patients did not complete the trial; 2 in the dapagliflozin arm 
(1 new diagnosis of metastatic lung cancer and 1 withdrawal of consent) and 
5 in the placebo arm (1 fatal myocardial infarction, 2 sudden cardiac death, 1 
relapse of previously treated cholangiocarcinoma, 1 withdrawal of consent). 
Of 23 patients in the placebo arm who completed the trial per-protocol, CMR 
images for one was excluded from analysis because of poor quality at baseline 
however, the non CMR data points were included in analysis. There were no 
instances of withdrawal from the trial due to emergency unblinding throughout 





Figure 13. REFORM Trial CONSORT Diagram  
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3.2 BASELINE CHARACTERISTICS   
The average age of the study population was 67.1 years with a male majority 
of 66.1% which is common in trials of cardiovascular disease. 87.5% of the 
cohort were in NYHA functional class I or II. The commonest aetiology for HF 
was ischemic heart disease, with mean CMR-derived LVEF of 45.5%.  
The majority of patients were on evidence-based HF medications including 
ACE-I / ARB, beta-blockers and loop diuretics. Only 41.1% of patients were 
on mineralocorticoid receptor antagonists reflecting the mild severity of LVSD 
in this cohort.  
With regard to T2DM therapy, just over half the cohort were on metformin and 
28.6% required add-on insulin. The baseline mean HbA1c was 60.9 mmol/mol, 
and the mean estimated glomerular filtration rate (eGFR) was 72.0 ml/min/1.73 
m2.  
The average duration of HF and T2DM were 6.2 and 8.8 years respectively. 
The commonest other co-morbidities were that of hypertension and previous 
myocardial infarction. The prevalence of atrial fibrillation in the REFORM 
cohort was 39.3% which was higher than the usual prevalence of 29.0% in UK 
patients with HF between 60-69 years old.(187) 
Both groups were comparable for age, gender and NYHA functional class as 
well as the majority of other baseline parameters. There were, however, 
differences in the baseline measurements of NT-proBNP, and urinary 
albumin:creatinine ratio between the groups, with the placebo group having 
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significantly higher median values (Table 10). It is important to note that these 
values were heavily skewed, and despite this difference, there was no 
difference in the NYHA functional class, BP, renal function, LV volumes and 


























Age (years) 67.1 6.9 66.9 7.0 67.4 6.8 0.788 
Male gender 37 66.1% 18 64.3% 19 67.9% 0.054 
Weight (kg) 91.5 18.6 92.9 18.1 90.2 19.3 0.587 
BMI (kg/m2) 32.5 5.3 33.0 5.5 32.0 5.2 0.495 
Functional Class:   
NYHA I 25 44.6% 12 42.9% 13 46.4% 0.794 
NYHA II 24 42.9% 13 46.4% 11 39.3% 0.546 
NYHA III 7 12.5% 3 10.7% 4 14.3% 0.245 
Blood pressure / Heart Rate:  
SBP (mmHg) 133.9 17.1 135.0 15.4 132.8 18.8 0.627 
DBP (mmHg) 72.7 10.0 74.0 7.1 71.4 12.2 0.328 
MAP (mmHg) 93.1 10.4 94.4 7.3 91.9 12.8 0.373 
HR (bpm) 76.0 12.8 77.6 14.0 74.4 11.6 0.354 
Duration of disease:  
Heart failure 
(years) 
6.24 6.49 6.64 6.07 5.83 6.99 0.649 
Type 2 diabetes 
(years) 
8.77 6.26 8.41 6.45 9.14 6.17 0.672 
Table 7. Baseline demographic data 
Abbreviations:  Med=Median; SD=Standard deviation; IQR=Interquartile 
range; CI=Confidence interval; kg= kilograms; BMI=body mass index; 
119 
 
NYHA=New York Heart Association functional classification for heart failure; 
SBP= systolic blood pressure; DBP=Diastolic blood pressure; MAP=Mean 























Etiology of heart failure:   
IHD 30 53.6% 15 53.6% 15 53.6% 0.845 
DCM 13 23.2% 7 25.0% 6 21.4% 0.456 
Other 11 19.6% 5 17.9% 6 21.4% 0.124 
Unknown 2 3.6% 1 3.6% 1 3.6% 1.000 
Co-morbidities:  
Hypertension 40 71.4% 22 78.6% 18 64.3% 0.485 
AF  22 39.3% 11 39.3% 11 39.3% 0.998 
PAD 9 16.1% 5 17.9% 4 14.3% 0.842 
Stroke / TIA 10 17.9% 3 10.7% 7 25.0% 0.060 
MI 29 51.8% 14 50.0% 15 53.6% 0.475 
Medications:   
Loop diuretic 
dose (mg)* 
49.8 22.0 52.9 20.5 46.8 23.4 0.307 
ACE-I/ARB 50 89.3% 25 89.3% 25 89.3% 0.985 
Beta blockers 46 82.1% 24 85.7% 22 78.6% 0.877 
MRA 23 41.1% 13 46.4% 10 35.7% 0.898 
Metformin 31 55.4% 17 60.7% 14 50.0% 0.978 
Other OHA 22 39.3% 13 46.4% 9 32.1% 0.413 
Insulin 16 28.6% 6 21.4% 10 35.7% 0.657 
Table 8. Aetiology of HF, co-morbidities and concurrent medications 
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Abbreviations: IHD=Ischemic heart disease; DCM=Dilated cardiomyopathy; 
AF=Atrial fibrillation; PAD=Peripheral arterial disease; TIA=Transient ischemic 
attack; MI=Myocardial infarction; ACE-I=Angiotensin converting enzyme 
inhibitor; ARB=Angiotensin receptor blocker; MRA=Mineralocorticoid receptor 
antagonist; OHA=Oral hypoglycemic agent. 
* Bumetanide dose converted to equivalent furosemide dose (1mg bumetanide 























Cardiac MRI Parameters:  
LVEDV (ml) 180.2 61.0 172.4 47.7 188.3 72.4 0.346 
Indexed LVEDV 
(ml/m2)  90.3 30.9 85.9 24.1 95.0 36.8 0.294 
LVESV (ml) 102.7 50.5 99.2 40.7 106.4 59.6 0.604 
Indexed LVESV 
(ml/m2) 51.6 26.2 49.4 21.3 54.1 30.9 0.520 
LV Mass Index 
(g/m2) 71.5 17.7 69.5 16.3 73.7 19.3 0.398 
LVEF (%) 45.5 12.0 44.5 12.4 46.5 11.7 0.526 
LV Stroke Vol 
(ml) 38.7 10.4 36.6 10.4 41.0 10.2 0.126 
Indexed LA 
Volume(ml/m2)† 50.0 18.9 49.0 18.8 51.0 19.3 0.699 
Table 9. Cardiac Magnetic Resonance Imaging parameters at baseline 
Abbreviations:  LVEDV=Left ventricular end diastolic volume; LVESV=Left 
ventricular end systolic volume; LVEF=Left ventricular ejection fraction; 
LV=Left ventricular; LA=Left atrial 
* = Unable to analyse baseline images of one participant in placebo group due 
to very poor image quality 
† = Unable to analyze baseline LA volume in 5 patients due to poor image 























 Biochemistry:  
 Hb (g/dL)  13.5 1.6 13.2 1.3 13.8 1.5 0.294 
Hct (%) 40.9 4.7 40.4 3.9 41.4 5.4 0.405 
HbA1c 
(mmol/mol) 60.9 17.1 63.0 17.8 58.6 16.4 0.339 
Creatinine 
(µmol/L)  88.2 19.9 92.0 19.9 84.4 19.5 0.151 
eGFR 
(ml/min/1.73m2) 72.0 19.2 67.7 16.4 76.2 21.0 0.254 
BHB (mmol/L) 0.2 0.1 0.2 0.1 0.2 0.1 0.865 
Biomarkers:  
NT-ProBNP 
(pg/ml) (1781.6) (4910.4) (1567.9) (1735.1) (3717.3) (5846.6) 0.028 
hsCRP (mg/L) (3.3) (6.6) (3.3) (4.8) (3.8) (7.4) 0.873 
Oxi-LDL (u/ml) 54.3 19.2 59.2 19.8 49.4 17.6 0.054 
Urinary measurements:  
Urine Na 
(mmol/L) 80.7 33.6 79.0 32.6 82.4 35.0 0.708 
Urine Alb (mg/L) (13.0) (40.8) (9.0) (29.0) (19.0) (53.5) 0.132 
Urine ACR 
(mg/mmol) (2.9) (10.2) (1.8) (5.4) (4.4) (14.0) 0.0503 
Table 10. Blood and urine investigations at baseline 
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Abbreviations: Hb=Haemoglobin; Hct=Haematocrit; HbA1c=Haemoglobin 
A1c; eGFR=Estimated glomerular filtration rate; NT-proBNP=N-terminal pro 
B-type natriuretic peptide; hsCRP=High sensitivity C-reactive protein; Oxi-

























 Cardiopulmonary exercise test parameters:  
V02 Max* 
(ml/min) 1290.0 350.0 1290.0 350.0 1300.0 360.0 0.979 
VC02 Max* 
(ml/min) (1200.0) (530.0) (1210.0) (500.0) (1170.0) (540.0) 1.000 
Peak Ve*  
(L/min) 50.7 14.7 50.2 14.1 51.3 15.6 0.782 
Normalized V02 
Max*(ml/kg/min) 14.3 3.4 14.1 3.3 14.5 3.5 0.659 
Ve/VCO2 slope* 37.6 6.8 36.3 6.3 38.9 7.2 0.213 
Respiratory 
exchange ratio* 0.97 0.1 0.97 0.1 0.96 0.1 0.802 
Six-minute walk test:  
Distance (m) 398.2 128.9 404.3 113.8 392.2 144.4 0.857 
Quality of life questionnaires:  
SF-36 PCS 50.0 10.6 50.4 10.9 49.5 10.5 0.747 
SF-36 MCS 49.5 9.9 51.2 10.6 47.9 9.1 0.226 
MLHF (24.5) (30.0) (22.0) (31.0) (25.5) (27.8) 0.712 
Table 11. Exercise capacity and quality of life measures at baseline 
 
Abbreviations:  V02 Max=Peak oxygen consumption; VC02 Max=Peak carbon 
dioxide production; Ve=minute ventilation; Ve/VCO2= peak minute ventilation 
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to carbon dioxide ratio; SF-36 PCS=Physical component summary of the short 
from 36; SF-36 MCS=Mental component summary of the short from 36; 
MLHF=Minnesota living with heart failure.  
*=Analysis excludes 2 patients in placebo arm who were unable to complete 
CPET   
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3.3 CARDIAC MRI FINDINGS 
At the end of one year, per-protocol analysis revealed no significant difference 
in LV volumes of patients in both groups when adjusted for baseline ventricular 
volumes, age, sex and renal function. Both LVEDV and LVESV were reduced 
in dapagliflozin and placebo groups (LVEDV: dapagliflozin -6.9 ±35.9ml vs. 
placebo -12.8 ±41.4ml, adjusted treatment effect +4.15ml; 95% CI -18.52-
26.83, p=0.714; LVESV: dapagliflozin -7.0 ±26.7ml vs. placebo -8.1 ±36.5ml, 
adjusted treatment effect +0.96ml; 95% CI -17.07-19.00, p=0.915). There was 
no significant difference in LVEF (dapagliflozin +2.1 ±5.9% vs. placebo -0.3 
±8.7%, adjusted treatment effect +1.98%; 95% CI -2.18-6.14, p=0.342) or 
LVMI (dapagliflozin +3.7 ±10.1g/m2 vs. placebo +3.6 ±8.9 g/m2, adjusted 
treatment effect -0.05 g/m2; 95% CI -5.98-5.89, p=0.970) 
Sensitivity analysis was performed as per the prespecified analytical protocol 
using intention to treat; the observed effects were unchanged. A further post-
hoc sensitivity analysis was performed using the per-protocol dataset 
controlling for baseline NT-proBNP as this was unexpectedly different between 














Mean SD Mean SD 
LVEDV (ml) -6.9 35.9 -12.8 41.4 
4.15                         




-3.4 15.7 -6.6 20.5 
1.93                         
(-8.57 to 12.43) 
0.713 
LVESV (ml) -7.0 26.7 -8.1 36.5 
0.96 




-3.3 12.3 -4.1 18.1 
0.51 
(-10.97 to 11.99) 
0.929 
LVEF (%) 2.1 5.9 -0.3 8.7 
1.98 
(-2.18 to 6.14) 
0.342 
LV Indexed Mass 
(g/m2) 
3.7 10.1 3.6 8.9 
-0.05                            




LV Stroke Vol (ml) 
-0.3 6.5 -2.5 6.6 
1.50                    
(-2.27 to 5.27) 
0.426 
Indexed LA Volume 
(ml/m2)† 
-2.7 11.8 -3.5 14.9 
-2.45   
(-10.62 to 5.71)  
0.546 
Table 12. Cardiac MRI outcomes 
 
Abbreviations: SD=Standard deviation; CI=Confidence interval; LVEDV=Left 
ventricular end diastolic volume; LVESV=Left ventricular end systolic volume; 
LVEF=Left ventricular ejection fraction; LV=Left ventricular  
* =1 patient in placebo group excluded from analysis due to uninterpretable 
baseline CMR films – dapagliflozin (n=26), placebo (n=22) 
† = 6 patients excluded due to poor baseline and or final image quality 








3.4 METABOLIC AND HAEMODYNAMIC EFFECTS   
After 1 year of treatment, dapagliflozin caused a reduction in body weight that 
approached statistical significance (dapagliflozin -1.9 ±3.8kg vs. placebo -0.9 
±4.7kg, adjusted treatment effect -1.97kg; 95% CI -3.99-0.05, p=0.056). 
However, when the full dataset was analyzed (to include the two large outliers) 
the adjusted treatment effect was -0.89kg; 95% CI -3.31-1.53, p=0.464. There 
was a significant reduction in diastolic blood pressure (dapagliflozin -0.1 
±7.5mmHg vs. placebo +6.1 ±11.1mmHg, adjusted treatment effect -
6.58mmHg; 95% CI -11.93 - -1.23, p=0.017). Systolic blood pressure was 
numerically lower in the dapagliflozin arm (dapagliflozin -3.5 ±19.3mmHg vs. 
placebo +2.4 ±19.4mmHg, adjusted treatment effect -4.80mmHg; 95% CI -
16.04-6.44, p=0.39). Despite reduction in blood pressure there was no 
increase in heart rate (dapagliflozin -3.0 ±9.3 beats/min vs. placebo -2.0 ±11.6 












Mean SD Mean SD 
Weight†  (kg) -1.9 3.8 -0.9 4.7 
-1.97 




SBP (mmHg) -3.5 19.3 2.4 19.4 
-4.80                          
(-16.04 to 6.44) 
0.394 
DBP (mmHg) -0.1 7.5 6.1 11.1 
-6.58 
(-11.93 to -1.23) 
0.017 
MAP (mmHg)  -1.2 9.9 4.9 13.1 
-5.99 




-3.0 9.3 -2.0 11.6 
0.40 
(-5.67 to 6.48) 
0.894 
Table 13. Metabolic and haemodynamic outcomes 
 
Abbreviations: SBP=Systolic blood pressure; DBP=Diastolic blood pressure; 
MAP= Mean arterial pressure 
†=analysis excludes 1 patient from each arm due to excessive weight gain and 







3.5 BLOOD AND BIOCHEMISTRY 
Patients in the dapagliflozin arm saw a significant increase in haemoglobin 
(dapagliflozin +1.2 ±1.1g/dL vs. placebo -0.1 ±0.8g/dL, adjusted treatment 
effect +1.16g/dL; 95% CI 0.60-1.74, p<0.001) and haematocrit (dapagliflozin 
+4.0 ±3.0% vs. placebo 0.0 ±3.0%, adjusted treatment effect +3.59%; 95% CI 
1.87-5.31, p<0.001). Dapagliflozin also caused a modest but significant 
increase in BHB (dapagliflozin +0.03 ±0.06mmol/L vs. placebo 0.00 
±0.06mmol/L, adjusted treatment effect +0.04mmol/L; 95% CI 0.001-0.08, 
p=0.045). Notably, there was no significant difference in log NT-proBNP at the 
end of the trial, (dapagliflozin -0.1 ±0.8 pg/mL vs. placebo -0.2 ±0.9 pg/mL, 
adjusted treatment effect 0.00 pg/mL; 95% CI -0.53-0.53, p=0.993) even in 
additional sensitivity analysis adjusting for body weight.  
Unexpectedly, in the treatment arm, we also observed a significant increase 
in oxidized-LDL (oxi-LDL) (dapagliflozin +2.0 ±12.6 u/mL vs. placebo -5.6 
±15.2 u/mL, adjusted treatment effect +10.70 u/mL; 95% CI 3.22-18.19, 
p=0.006) and reduction in urinary sodium excretion (dapagliflozin -13.7 
±50.6mmol/L vs. placebo +5.7 ±31.7mmol/L, adjusted treatment effect -














Mean SD Mean SD 
Haemoglobin 
(g/dL) 
1.2 1.1 -0.1 0.8 
1.16 
(0.60 to 1.74) 
<0.001 
Haematocrit (%) 4.0 3.0 0.0 3.0 
3.59 




0.03 0.06 0.00 0.06 
0.04 




2.0 12.6 -5.6 15.2 
10.70 
(3.22 to 18.19) 
0.006 
Log hsCRP (mg/L) 0.0 1.1 -0.3 0.9 
0.16 






5.1 12.9 6.6 9.5 
-2.42 




-1.5 12.5 -6.9 10.8 
4.23 
(-2.81 to 11.27) 
0.232 
Log NT-proBNP  
(pg/ml) 
-0.1 0.8 -0.2 0.9 
0.00 




-3.3 9.3 -1.4 11.4 
-1.30  




-13.7 50.6 5.7 31.7 
-16.9 
(-37.12 to -3.34) 
0.036 
Log Urine albumin 
(mg/L) 
0.1 1.6 -0.6 1.8 
0.20 
(-0.85 to 1.25) 
0.704 
Log Urinary ACR 0.0 1.1 -0.5 0.8 
0.30 




Table 14. Blood and biochemistry outcomes 
Abbreviations: BHB=Beta-hydroxybutyrate; LDL=Low density lipoprotein; 
hsCRP=High sensitivity C-reactive protein; eGFR=Estimated glomerular 
filtration rate; NT-proBNP=N-terminal pro B-type natriuretic peptide; 
Na=Sodium; ACR=Albumin:creatinine ratio  
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3.6 LOOP DIURETIC THERAPY  
Patients on the dapagliflozin arm required less loop diuretic therapy compared 
to those on placebo (dapagliflozin -16.9 ±18.5mg vs. placebo 9.1 ±28.8%, 
adjusted treatment effect -28.04mg; 95% CI -42.35- -13.74, p<0.001) and were 
more likely to stop or reduce their loop diuretic dose; 50.0% vs 8.7%; p=0.005.  
 
 
Figure 14. Loop diuretic dose trend 
 
Note bumetanide dose converted to equivalent furosemide dose (1mg 




Figure 15. Changes in loop diuretic requirements 
 
Note bumetanide dose converted to equivalent furosemide dose (1mg 







3.7 EXERCISE TOLERANCE AND BODY COMPOSITION 
There was no significant difference between the two groups with regard to 
measures of exercise tolerance such as CPET parameters or 6MWT distance. 
Similarly, there was no difference between groups in total body fat or water 
content at the end of the trial.   
Unfortunately, due to improper technique in the final CPET assessment (ill-
fitting mask, poor adherence to exercise protocol and early termination of test), 
a total of 6 patients had to be excluded from final analysis. This was due to the 
delegation of trial data collection duties to research nurses as the principal 




Placebo      
(n=23) Adjusted treatment 
effect (95% CI) 
p 
value 
Mean SD Mean SD 
VO2 Max* (ml/min)  -0.1 0.3 -0.1 0.4 
0.02 
(-0.19 to 0.24) 
0.848 
Log VCO2 Max* 
(ml/min)  
-0.1 0.3 -0.2 0.6 
0.08 




Peak Ve* (L/min) -2.1 8.9 -1.9 11.3 
0.64 
(-5.92 to 7.20) 
0.845 
Normalized VO2 
Max*  (ml/kg/min) 
2.8 16.5 -1.0 3.6 
3.28                         




-0.0 0.1 -0.0 0.1 
-0.01 
(-0.05 to 0.02) 
0.420 
Ve/VCO2 Slope* 1.3 4.9 0.4 7.4 
1.95 
(-1.94 to 5.84) 
0.315 
6MWT distance  
 (m) 
-14.1 81.9 1.7 45.3 
-20.71 
(-62.19 to 20.78) 
0.320 
Total body fat (%) -0.1 2.6 -0.3 2.8 
0.42 
(-1.06 to 1.91) 
0.571 
Total body water (%) -0.2 1.4 0.0 1.6 
-0.38 
(-1.18 to 0.43) 
0.351 




Abbreviations:  V02 Max=Peak oxygen consumption; VC02 Max=Peak carbon 
dioxide production; Ve=minute ventilation; Ve/VCO2= peak minute ventilation 
to carbon dioxide ratio; 6MWT=Six-minute walk test 
*=analysis excludes 6 patients due to incorrect CPET technique / 
uninterpretable data at final visit test. (dapagliflozin n=25 and placebo n=18). 
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3.8 QUALITY OF LIFE 
There was no difference in all measures of general or specific quality of life 





Placebo      
(n=23) Adjusted treatment 
effect (95% CI) 
p 
value 
Mean SD Mean SD 
SF-36 PCS 0.2 6.4 -0.1 5.9 
-0.06                        
(-3.50 to 3.37) 
0.970 
SF-36 MCS -0.4 10.5 -0.1 7.3 
1.33                         
(-3.93 to 6.59) 
0.614 
MLHFQ -1.2 18.7 0.6 20.8 
-1.19 
(-12.08 to 9.69) 
0.826 
Table 16. Quality of life outcomes 
 
Abbreviations: SF-36 PCS=Physical component summary of the short from 
36; SF-36 MCS=Mental component summary of the short from 36; 
MLHF=Minnesota living with heart failure      
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3.9 ADVERSE EVENTS  
There was a total of 5 deaths during the trial period; 1 in the dapagliflozin arm 
and 4 in the placebo arm, 3 of them CV deaths. There was a total of 4 instances 
of decompensated HF, one of them recurrent in a participant who was on 
placebo. There were 3 cases of acute coronary syndromes; 1 each of a fatal 
myocardial infarction, non-STEMI and unstable angina, all occurring in the 
placebo arm.  
We observed numerically more cases of urinary tract infections / genital 
infections in the dapagliflozin arm compared to placebo; 5 vs 2 cases. Two 
patients had recurrent infections, both were on dapagliflozin. All instances of 
infection were treated by the GP without having to withdraw / withhold therapy.  
There were significantly more instances of major worsening of renal function 
(defined as >20% increase in creatinine or eGFR <45 ml/min/1.73 m2) in the 




Adverse Event Breakdown:  
There were 64 recorded instances of AEs, 13 of which were SAEs. None of 
the SAEs were attributed to the study drug. Of the 51 AEs 17 were classified 
as drug-related in the dapagliflozin group, while there were 7 such events in 
the placebo group.  
 
SAEs in Dapagliflozin group (3 events):  
 Decompensated HF  
 New diagnosis of metastatic lung cancer  
 Gastroenteritis requiring hospitalisation  
 
SAEs in Placebo group (10 events):  
 Decompensated HF  
 Recurrence of cholangiocarcinoma  
 Gastroenteritis requiring hospitalisation  
 Acute coronary syndrome (3 individuals)  
 Cardiac arrest from ventricular fibrillation (2 individuals)  
 Community acquired pneumonia requiring hospitalisation  





The following are some key adverse events of interest:  
 
Parameter Dapagliflozin Placebo p value 
All cause death 1 4 0.349 
Fatal MI 0 1 1.00 
Sudden cardiac death 0 2 0.472 
Non-CV death  1 1 1.00 
Decompensated HF 1 3 0.604 
Non-fatal ACS 0 2 0.472 
Cancer (new / recurrence)  1 1 1.00 
Other hospitalizations 1 3 0.604 
Major WRF*  8 0 0.008 
Minor WRF* 0 2 0.472 
Symptomatic hypoglycemia 4 2 0.666 
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Dehydration  3 0 0.235 
UTI / genital infections 5 2 0.419 
Other non-serious adverse 
events 
12 15 0.593 
Table 17. Adverse events 
 
Abbreviations: MI=Myocardial infarction; CV=Cardiovascular; HF=Heart 
failure; ACS=Acute coronary syndrome; WRF=Worsening renal function; 
UTI=Urinary tract infection  
*= Major WRF was defined as >20% increase in creatinine or eGFR <45 
ml/min/1.73 m2. Minor WRF was defined as a sustained increase in creatinine 




3.10 EXPLORATORY ANALYSIS 
The inclusion criteria for the REFORM trial stipulated that patients had to have 
a diagnosis of HF with echocardiographic evidence of LV systolic dysfunction 
defined as LVEF <45% or at least mild dysfunction on subjective assessment 
by the sonographer. Although it was not ideal to use a subjective assessment 
of LV function for inclusion, the vast majority of echocardiography reports in 
the Tayside region did not objectively measure LV function (e.g. by Simpson’s 
biplane or global longitudinal strain) meaning it would have been extremely 
difficult to recruit patients by screening electronic health records. Pre-
recruitment echocardiography would have resolved this issue but due to 
limited funding and staff availability, this was not an option.  
This resulted in some patients with LVEF that were ≥45% being recruited into 
the trial as evidenced the CMR-derived baseline LVEF range of 20.0% to 75%. 
Although there is an expected difference between these measurements using 
two very different imaging modalities, this introduced heterogeneity into the 
cohort and made it difficult to investigate the true effects of the drug in patients 
with ongoing HFrEF.  
To mitigate this, we performed a post-hoc, exploratory analysis by looking for 
an interaction between LVEF and treatment allocation. We used an LVEF 
cutoff of 45% as the interaction term in the regression model, thus allowing 
analysis of the cohort as originally intended by the inclusion criteria. Interaction 
analysis is superior to simply splitting the cohort and performing subgroup 
analysis on those with baseline LVEF<45% because with interaction analysis 
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the population size is not reduced, thereby preserving the overall power of the 
analysis.  
Table 18 and Table 19 show some key baseline and final measurements for 
both subgroups. We then re-ran the regression model with the interaction term 
of baseline LVEF for the primary outcome and relevant secondary outcome 
measures. The key findings of this analysis are summarized in Figure 16. 
Significant interactions were found only in LVEDV, LVESV and LVMI. 
Unexpectedly, it showed that patients with higher baseline LVEF (≥45%) saw 
LV reverse remodelling while those with lower LVEF didn’t. There was no 
interaction seen between baseline LVEF and dapagliflozin in other secondary 
outcomes.  
We were keen to understand the reason for this differential effect and ascertain 
if there were any confounders that were masking the true mechanism behind 
this. We first tested if change in BP influenced LV remodelling - BP reduction 
is an established factor in inducing reverse remodelling,(188-192) and 
observing this would help validate our data. Indeed, we observed that SBP 
reduction was associated with significant reductions in LVEDV, LVESV and 
LVMI; there was a -1.11ml (95% CI -0.58 to -1.63, p<0.001), -0.69ml (95% CI 
-0.24 to -1.13, p=0.004) and -0.26ml (95% CI -0.12 to -0.40, p<0.001) 
reduction respectively for every 1mmHg reduction in SBP. However, change 
in SBP had no effect on LVEF. These effects were independent of baseline 
LVEF.   
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Having established that reduction in SBP led to LV reverse remodelling in the 
entire cohort, regardless of baseline LVEF, we wanted to determine if there 
was a difference in the blood pressure reduction achieved between those with 
higher LVEF (≥45%) and lower LVEF (<45%) at baseline. There was a greater 
reduction in BP achieved in the higher LVEF group by -11.35/-5.60 mmHg 
(Psbp=0.046/Pdbp=0.038), adjusted for baseline BP, age, sex and baseline 
eGFR. Importantly, there was no interaction between baseline LVEF and 
treatment allocation with regard to change in BP, (Pinteraction=0.055 for SBP and 
Pinteraction=0.118 for DBP) in other words, the effect of dapagliflozin on BP was 
unaffected by baseline LVEF. This suggested that there was another reason 
behind this difference in BP reductions between the LVEF groups.  
Interestingly, although both LVEF subgroups saw reductions in mean loop 
diuretic doses when on dapagliflozin, there was significantly greater reduction 
in loop diuretic dose in the lower LVEF group (Pinteraction=0.010). This was very 
likely driven by lower baseline eGFR in the dapagliflozin arm of the lower LVEF 
subgroup (Table 19) which would have deteriorated further following increased 
diuresis caused by the trial drug. We also observed patients with any reduction 
in loop diuretic dose ended up with higher mean final SBP (p=0.016) but not 
DBP (p=0.482). We confirmed that change in loop diuretic dose alone did not 
result in any significant changes in measures of LV remodelling. 
The implications of these exploratory, post hoc findings are discussed in detail 




BASELINE LVEF < 45%     (n=19)  BASELINE LVEF ≥ 45%     (n=29) 
DAPA  (n=11) PLACEBO  (n=8) *p-
value 
DAPA  (n=15) PLACEBO (n=14) *p-
value Median IQR Median IQR Median IQR Median IQR 
Start LVEDV 182.9 32.4 230.1 93.5 0.216 163.4 65.2 137.0 82.4 0.541 
Final LVEDV 175.8 35.5 183.6 65.8 0.934 144.7 43.6 145.1 68.3 0.861 
Absolute diff -7.1  -46.5  0.058 -18.7  8.1  0.359 
Start LVESV 123.9 29.8 149.95 74.5 0.509 75.5 44.0 64.8 36.6 0.760 
Final LVESV 114.6 18.6 105.6 55.7 0.680 65.8 24.8 59.1 47.5 0.793 
Absolute diff -9.3  -44.35  0.117 -9.7  -5.7  0.176 
Start LVMI 72.1 15.3 84.2 16.9 0.248 69.6 18.4 64.4 24.7 0.861 
Final LVMI 73.3 17.1 79.8 19.8 0.869 69.3 22.0 69.9 27.6 0.541 
Absolute diff 1.2  -4.4  0.364 -0.3  5.5  0.064 
Start LVEF 32.7 8.1 41.7 8.7 0.058 52.0 8.7 49.8 10.1 0.727 
Final LVEF 36.3 8.6 44.9 4.4 0.026 56.4 8.6 50.0 18.0 0.285 
Absolute diff 3.6  3.2  0.620 4.4  0.2  0.070 
Table 18. Measures of LV remodelling split by baseline LVEF 
Abbreviations: LVEDV=Left ventricular end diastolic volume; LVESV=Left 
ventricular end systolic volume; LVEF=Left ventricular ejection fraction; 
LVMI=Left ventricular indexed mass; Diff=Difference; DAPA=Dapagliflozin; 
IQR=Interquartile range  


















Median IQR Median IQR Median IQR Median IQR 
Start Weight  94.4 15.9 85.2 17.0 0.186 97.0 21.6 92.1 15.9 0.631 
Final Weight 97.5 16.8 85.5 9.3 0.186 92.4 16.9 92.4 14.6 0.861 
Absolute diff 3.1  0.3  0.680 -4.6  0.3  0.032 
Start SBP 130.0 30.5 129.5 35.8 0.901 142.0 22.0 127.0 29.0 0.678 
Final SBP 139.0 22.5 131.0 15.3 0.282 121.0 14.5 138.5 35.8 0.097 
Absolute diff 9.0  1.5  0.710 -21  11.5  0.042 
Start DBP 73.0 9.5 76.5 16.8 0.934 72.0 8.5 73.0 10.5 0.693 
Final DBP 75.0 12.5 74.5 12.5 0.934 70.0 7.0 80.0 15.8 0.006 
Absolute diff 2  -2  0.281 -2  7  0.019 
Start eGFR 60.4 22.0 76.5 13.0 0.039 68.4 33.6 67.1 36.9 0.485 
Final eGFR 56.6 27.6 70.6 13.4 0.186 69.5 27.4 67.9 29.4 0.695 
Absolute diff -3.8  -5.9  0.283 1.1  0.8  0.570 
Start Loop dose 60.0 40.0 40.0 12.5 0.083 40.0 30.0 40.0 40.0 0.602 
Final Loop dose 40.0 0.0 60.0 40.0 0.127 40.0 20.0 40.0 40.0 0.159 
Absolute diff -20  20  0.002 0  0  0.082 
Table 19. Key secondary outcome measures split by baseline LVEF 
 
Abbreviations: LVEF= Left ventricular ejection fraction; SBP= Systolic blood 
pressure; DBP= Diastolic blood pressure; eGFR= estimated glomerular 
filtration rate; Diff=Difference; DAPA=Dapagliflozin; IQR=Interquartile range  




































































































































































































































































4. DISCUSSION  
4.1 OVERVIEW 
The REFORM trial showed that 1 year of dapagliflozin therapy in individuals 
with T2DM and HF did not result in a significant effect on measures of LV 
remodelling. Nevertheless, it also showed that the effects of SGLT2-inhibition 
such as weight loss, blood pressure reduction, increased diuresis, ketogenesis 
and increased haemoglobin / haematocrit which were previously 
demonstrated in the T2DM population is maintained in the HF cohort.  
Although we were unable to identify any direct ‘morphological’ changes in the 
heart by way of remodelling, there may be molecular changes such as 
improved myocardial energetics that could be responsible for the impressive 
morbidity and mortality outcomes seen in the large CV outcome trials of 
SGLT2-inhibitors so far. Although this was not directly studied by this work, we 
did observe surrogates that suggest, at the very least, dapagliflozin therapy 
provides a suitable milieu to enhance myocardial energy efficiency in the 
setting of HF. This will need to be confirmed by other dedicated mechanistic 
trials in the future.  
In exploratory analysis, we found a signal suggesting that dapagliflozin may 
result in LV reverse remodelling in patients with LVEF ≥ 45%. There may be 
two potential mechanisms for this; firstly, we speculate that patients with more 
advanced LVSD may not have been able to respond to improvements in 
myocardial energy efficiency conferred by dapagliflozin therapy due to more 
extensive cardiomyocyte damage. Secondly, our observations may have been 
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confounded by a disproportionately larger reduction in loop diuretic dose in the 
LVEF < 45% subgroup on dapagliflozin, which resulted in higher LV loading 
conditions thereby preventing reverse remodelling.  
There were also no serious safety concerns around the use of dapagliflozin in 
our cohort, with a transient and reversible decline in renal function (which is 
an expected effect of a diuresis-inducing drug) being the only concern.   
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4.2 LEFT VENTRICULAR REMODELLING   
Changes in parameters of LV remodelling (i.e. LV volumes, EF and mass) 
have long been shown to be markers of survival in patients with CV 
disease.(193-195) LVESV in particular, has been shown to be an important 
predictor of survival in a range of patients with cardiovascular disease, and 
reducing it is associated with improved outcomes in numerous therapeutic 
trials.(194,196,197)  
In the EMPA-REG OUTCOME trial there was an early divergence of the 
survival curves for mortality and MACE (at around 3 months), and an even 
earlier divergence in HF hospitalisation. A similar pattern was seen in the 
CANVAS trial (for MACE and HF hospitalisation) and DECLARE-TIMI 58 (for 
HF hospitalisation). This early divergence suggests that SGLT2-inhibition 
probably has a benefit profile that differs from the classical CV risk reduction 
by way of improved glycaemia, weight loss and BP control alone. The prime 
‘mechanistic’ candidate was the diuretic effect of SLGT2-inhibitors, which we 
concluded, should result in reduced LV volumes in the first instance.  
This work showed that 1 year of dapagliflozin therapy had no effect on 
measures of LV remodelling. It is perhaps not altogether surprising as our 
findings are actually consistent with a number of pre-clinical and clinical 
studies. Rodent T2DM models using empagliflozin showed improvements in 
diastolic function but no effect on LV volumes or LVEF. (198,199) In a small, 
open labelled, uncontrolled clinical trial of 10 patients with T2DM and CV 
disease (but no HF), Verma et al. demonstrated that 3 months of empagliflozin 
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therapy lead to improvements in LVMI and measures of diastolic function but 
not LV volumes or LVEF. This study was limited by the use of 
echocardiography and a relatively short observation period.(200) In a more 
recent study by the same group (EMPA-HEART Trial), this time using CMR in 
a larger cohort of 96 individuals with T2DM and CV disease (6% with HF), they 
found that 6 months of empagliflozin therapy vs placebo resulted in reduction 
in LVMI by -2.6 vs -0.01 g/m2 (with the greatest improvements occurring in 
those with higher baseline LVMI). Once again, there was no effect on LV 
volumes or EF.(201)  
The reason why dapagliflozin therapy was neutral on LV remodelling may be 
twofold: Firstly, the effects of current-generation HF therapy (such as BB, 
ACE-I / ARB and MRA) on LV remodelling are well documented.(192,202,203) 
The majority of patients in the REFORM trial were on BB and ACE-I/ARB 
(>80%) and 41.1% were on an MRA. Although we were unable to determine 
the duration of these medications, with an average duration of confirmed HF 
of 6.2 years it would be fair to say that the patients would have been on them 
for some time. These drug classes have a much more potent effect on 
ventricular loading than the modest effects seen by SGLT2-inhibitors, 
therefore any further improvement in parameters of LV remodelling would be 
difficult to achieve. Additionally, the REFORM cohort only had mildly increased 
LV volumes, mild impairment of LVEF, and normal LVMI.  
Secondly, and perhaps more interestingly, the reason why there was such a 
striking improvement in HF outcomes in the large trials in spite of a lack of 
effect on LV remodelling could be because SGLT2-inhibitors act in a novel way 
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that is not reflected by changes in LV remodelling as we currently understand 
them. There is evidence demonstrating SGLT2-inhibitors improve myocardial 
energetics, ion exchange, necrosis and fibrosis pathways which may 
potentially contribute to overall outcomes.(152,153) We did not study these 
effects directly but there is indirect evidence from our findings to suggest that 
dapagliflozin induces changes that may support increased myocardial work 
efficiency, and this is discussed in the subsequent sections. Animal models 
show SGLT2-inhibition by empagliflozin affects myocardial sodium / hydrogen 
exchanger resulting in reduced cytoplasmic sodium and calcium 
concentration, while increasing mitochondrial calcium.(204) Other rodent and 
preliminary work on human cardiac fibroblast show dapagliflozin and 
empagliflozin prevent myocardial fibrosis by suppressing collagen synthesis 
via various mechanisms such as activation of M2 macrophages, inhibition of 
myofibroblast differentiation and attenuation of transforming growth factor 




4.3 METABOLIC AND HAEMODYNAMIC EFFECTS 
4.3.1 Weight  
One of the key benefits of SGLT2-inhibitor therapy in the T2DM population is 
weight loss. As discussed in section 1.6.2 of the introduction, the proposed 
mechanism of this weight loss is from calorific loss via glycosuria, increased 
lipolysis due to a shift in metabolism towards ketogenesis, and to a smaller 
extent, water loss from increased diuresis.(143,147)   
In the REFORM cohort, there was no statistically significant reduction in 
weight. We saw a nearly 2kg reduction in weight that was approaching 
significance in the group treated with dapagliflozin when 2 large outliers were 
excluded from analysis (see Section 2.11.2). When they were included in the 
regression model, the weight trend remained but statistical significance was 
lost completely. Interestingly, there was no significant difference in the 
proportion of fat, as determined by bioelectrical impedance, between the two 
groups. However, there was an increase in BHB which is a product of fat 
metabolism and can be considered as a surrogate for increased lipolysis. We 
believe the reason for this discordance may be due to a limitation in the test 
itself; bioelectrical impedance estimates the proportion of fat by subtracting fat-
free (lean) tissue from total body weight. Indeed a study by Browning et al. on 
a similar machine (from the same manufacturer as the one used in REFORM) 
showed that the fat measurement by the machine corelated well to total 
abdominal fat and waist circumference but not to visceral fat.(207) Visceral fat 
has been implicated in a number of diseases including IHD, hypertension, 
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T2DM and insulin resistance, colon, breast and prostate cancer and increased 
in-hospital mortality.(141) 
As SGLT2-inhibitors have been shown to increase lipolysis and have 
significant improvements in CV mortality, it follows that visceral fat is the likely 
target of this drug. Indeed a MRI sub-study of a 2-year trial of individuals with 
T2DM using dapagliflozin suggested a signal of proportionally more visceral 
fat loss than subcutaneous fat.(140)  The reason this was not observed in 
REFORM could be because visceral fat loss was not detected by the test we 
performed, and / or the readings were confounded by changes in the non-fat 
content such as interstitial and intravascular fluid volume as a result of diuresis. 
Ideally, we should have measured the visceral fat content using MRI which is 
the current gold standard (but that would have increased the scan duration 




4.3.2 Blood pressure and heart rate  
Patients in the dapagliflozin group had significantly lower diastolic BP and 
trends towards lower systolic BP and MAP, while there was no difference in 
their heart rate at the end of 1 year.  
It is important to note that the difference in diastolic BP between groups was 
due to higher pressures in the placebo group while those in the dapagliflozin 
group had not changed. SGLT2-inhibitiors have been shown to improve 
arterial stiffness and endothelial function, though the mechanisms are 
currently unclear.(147,152) Additionally, as discussed in section 1.6.3 of the 
introduction, SGLT2-inhbitors increase sodium delivery to the macula densa 
thereby indirectly lowering RAAS and sympathetic output. These effects 
account for the reduction in both systolic and diastolic BP seen in patients with 
T2DM. However, in the context of the REFORM cohort, these changes on 
systolic BP may be limited by the other, more potent, anti-hypertensive therapy 
the patients are already on.  
The lack of reflex tachycardia and sizeable reduction in MAP that approached 
significance is consistent with other work suggesting that SGLT2-inhibitors 
lower sympathetic outflow and vascular resistance, thereby potentially 
accounting for the larger effect on diastolic BP seen in REFORM.(208) 
Nevertheless, it is difficult to draw definitive conclusions on such mechanisms 
from this trial which was not designed (or sufficiently powered) to evaluate 




4.3.3 Diuresis   
We confirmed that dapagliflozin maintained its diuretic effect in the HF 
population who already were on chronic loop diuretic therapy. This is an 
important finding because there were concerns around over-diuresis and renal 
dysfunction when prescribing SGLT2-inhibitors to patients already on loop 
diuretics. Indeed, when this trial was conceived in 2014 there was no data on 
the interaction between these drug classes, forcing us to be cautious and 
designing a protocol that allowed for down-titration of loop diuretics if required.  
The diuretic effect of dapagliflozin was reflected by the 28.0 mg/day adjusted 
mean difference of loop diuretic dose between the two groups. This is a 
sizeable reduction in loop diuretic requirement considering this is a population 
of HF patients with a baseline mean loop diuretic dose of 49.8 mg/day that had 
been stable for at least three months (usually much longer). We also saw half 
the patients in the dapagliflozin arm either lower or come off loop diuretics 
completely. This loop diuretic-sparing effect reduces the overall pill burden, 
which in patients with HF, would be a welcomed change. Additionally, by using 
a different mechanism to achieve diuresis, it is feasible that SGLT2-inhibitors 
may be helpful in loop diuretic-resistant patients as well.   
Unfortunately, the safety provision in the trial protocol allowing for dose titration 
of loop diuretic therapy may have also resulted in confounding; there was no 
significant difference in the total water content, as measured by bioelectrical 
impedance, in spite of the large reduction in loop diuretic dose. If patients in 
the dapagliflozin group were left on their usual loop diuretic doses, this may 
have resulted in lower total water content and even perhaps lower LV volumes 
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at the end of 1 year. It is also important to recognise that none of the patients 
on the REFORM trial were on sacubitril/valsartan, which also has diuretic 
properties. The effects of concomitant SGLT2-inhibitor and sacubitril/valsartan 
use has not been studied therefore patients on this combination will have to 




4.4 MYOCARDIAL ENERGETICS  
Myocardial energetics is a new and exciting area of intense interest particularly 
with regard T2DM and HF. As alluded to in Section 1.3.2 (see Table 5) there 
is a shift toward the use of FFA as myocardial fuel in T2DM. This is a less 
efficient fuel substrate and the problem is compounded further in patients with 
dysfunctional hearts such as HF. SGLT2-inhibitors increase haemoglobin and 
ketone body levels which could help improve myocardial oxygen delivery as 
well as offer a more oxygen-efficient fuel substrate, thereby improving overall 
myocardial work efficiency.(62)(Figure 17) 
Indeed, in REFORM we observed a 1.16 g/dL increase in haemoglobin level 
and 0.04 mmol/L increase of the ketone body BHB, representing a 23.5% 
increase from the mean baseline value. We are unable to determine the true 
mechanism of these effects within the scope of this study, however we can 
infer that increased diuresis contributed to the rise in haemoglobin but, as 
discussed in Chapter 1.6.6, increased EPO synthesis is another likely factor. 
Similarly, increased BHB concentration is likely due to the increased lipolysis 
induced by SGLT2-inhibtion, but we are unable to confirm this in the present 
study.  
Although we did not study the effect of these changes on myocardial 
energetics directly, there is previous work demonstrating that even though 
skeletal muscle utilisation of ketone bodies is diminished in advanced HF, 
myocardial ketone body extraction remained unchanged.(209) However, the 
only way this hypothesis can be tested would be to conduct PET and CMR 
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studies to directly measure substrate uptake in various conditions using 
different radio-labelled fuels.  
If proven, this could explain why no changes to LV remodelling were seen in 
REFORM. The effects of SGLT2-inhibition on the major determinants of LV 
remodelling – ventricular preload and afterload (intravascular volume and 
blood pressure) – are modest at best. Perhaps all the beneficial effects of 
SGLT2-inhbition on the myocardium are occurring at the molecular level which 
are not manifested by morphological changes as measured by features of LV 
remodelling as we currently understand. Further study into this is warranted.  
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4.5 EXPLORATORY ANALYSIS  
Although there was no effect seen on measures of LV remodelling when the 
entire cohort was analysed, post-hoc exploratory analysis suggests 
dapagliflozin reduced LV volumes and indexed mass in patients with LVEF 
≥45%. Importantly, there was no interaction seen in all other key secondary 
outcomes such as weight, BP, Hb and BHB.  
These findings suggest that the cardiac effects of dapagliflozin are influenced 
by the individual’s LVEF when starting therapy; i.e. those with more severe 
LVSD (as suggested by a lower LVEF) have a poorer response to dapagliflozin 
with regard to LV remodelling. As alluded to in section 4.2, the ventricular 
loading effects of dapagliflozin are modest and is likely insufficient, in the case 
of advanced LVSD, to result in any appreciable difference in LV remodelling. 
Instead, in the subgroup of patients with LVEF≥45% - which could perhaps be 
considered as having HFpEF - improvements in LV remodelling were seen 
because the pathophysiology of HF differs significantly from those with HFrEF. 
The so-called ventriculo-vascular decoupling of HFpEF is a key consideration; 
current understanding suggest there are distinct haemodynamic (ventricular 
stiffness and fibrosis, left atrial hypertension, pulmonary vascular disease and 
volume expansion) and molecular (dysfunctional myocardial energetics, 
microvascular inflammation and cellular/extracellular structural abnormalities) 
changes involved in the pathophysiology of HFpEF.(210) Perhaps the effects 
of SGLT2-inhibition on diuresis, myocardial energetics (and other postulated 
effects on myocardial ion exchange and fibrosis) are more suited to HFpEF 
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compared to traditional HF therapies such as beta-blockers and RAAS-
inhibitors which are more effective in offloading more dysfunctional ventricles.    
Indeed this differential effect, preferring HFpEF, may also explain why such 
striking reductions in HF-related outcomes were seen in the large CV outcome 
trials which seemingly had very few patients with HF. It is conceivable that 
many of these patients with T2DM and CV disease (or high CV risk) actually 
had undiagnosed HFpEF which responded favourably to SGLT2-inhibition.  
It is also important to recognise that there was no interaction seen in other 
secondary outcomes. This means the ‘non-cardiac’ effects of dapagliflozin (e.g 
weight loss, diuresis, BP, Hb, BHB) were unaffected by baseline LVEF. In 
other words, all patients benefitted from these ‘non-cardiac’ effects, but those 
with LVEF ≥ 45% had additional benefit by way of improved LV remodelling.  
At first glance our findings appear to be in contradiction to the subgroup 
analysis from DECLARE TIMI-58(166) showing a mortality benefit in patients 
with LVEF < 45%. It is important to note that unlike REFORM where the LVEF 
data were all derived from CMR performed at recruitment into the trial, the 
LVEF data from DECLARE were from differing modalities (echocardiography, 
CMR, scintigraphy) which were done at varying (unspecified) time-points prior 
to recruitment. 88% of the patients in the HFrEF group in DECLARE TIMI-58 
were on ACE-i/ARB and beta-blockers so it is conceivable that the LVEF at 
the time of recruitment may well have been different from when the initial test 
was performed. It is also difficult to draw parallels between these studies 
because the end-points in DECLARE TIMI-58 was that of CV / all-cause 
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mortality after a four-year observation, while REFORM studied measures of 
LV remodelling after 1 year. The mortality reduction in the predominantly 
NYHA functional class I and II patients of DECLARE would have likely been 
driven by reduced sudden cardiac death from arrhythmias (rather than pump 
failure). This could be attributed to the improved intracytoplasmic ionic milieu 
and reduced fibrosis from SGLT2-inihbition, as discussed at the end of chapter 
4.2.   
Another important consideration that was uncovered by the exploratory 
analysis was that of the potential confounding effect of loop diuretic dose 
changes during the trial. We first confirmed that SBP reduction was associated 
with reduced LV volumes and mass for the entire cohort. We then identified 
that there was greater BP reduction in the higher LVEF subgroup compared to 
those with lower baseline LVEF. Importantly, there was no interaction between 
treatment allocation and LVEF grouping, suggesting that the effect of 
dapagliflozin was not modified by baseline LVEF. Further analysis revealed 
the reason behind this difference in BP effect between subgroups was due to 
a greater reduction in loop diuretic dose in the lower LVEF group. By play of 
chance, patients on the dapagliflozin arm of the lower LVEF subgroup had the 
highest loop diuretic dose and lowest eGFR at recruitment. (Section 3.10, 
Table 19) The additional diuretic effect of dapagliflozin resulted in an expected 
decline in renal function, triggering the safety protocol to scale back on loop 
diuretic dose. This could potentially explain the lack of BP reduction, and in 

















































































































































4.6 EXERCISE TESTS   
There was no difference in all major measures of CPET and the 6MWT 
distance between groups in REFORM. Although the mean baseline peak 
VO2/kg measurement may appear low at first glance, it is important to note 
that the mean respiratory exchange ratio was less than 1.0 indicating that it 
was a submaximal effort test.  
Improvement in peak VO2/kg has been associated with higher survival, but this 
is in the context of transplant candidates.(211) The prognostic value of peak 
VO2/kg starts to diminish the less severe the degree of HF. In an interesting 
trial-level meta-analysis of more than 70,000 individuals by Wessler and 
colleagues showed that drug or device-induced improvements in peak VO2 
and 6MWT did not correlate to the long term mortality outcomes of those 
interventions in patients with HFrEF.(212) 
Of course, the goal in REFORM was to determine if there was any objective 
improvement in measures of exercise tolerance; and we found none. 
Unfortunately, there were procedural shortcomings in conducting the final 
CPET for 6 patients (representing 12.2% of the per-protocol population) 
requiring exclusion from analysis which may have diluted the overall effect in 




4.7 QUALITY OF LIFE 
A SF-36 score of 50 for PCS and MCS is considered average, while a MLHF 
score of <24 is considered good. The REFORM cohort started with scores that 
reflected a moderate quality of life. After 1 year of dapagliflozin therapy there 
was no difference in the general (SF-36) and disease specific (MLHF) quality 
of life measures. 
It is perhaps not unexpected that there wasn’t any change in the perceived 
quality of life in this cohort as the changes seen in other clinical parameters 
(eg weight, BP etc) were modest. It is likely that there will have to be a 
sustained effect for a longer duration before patients will start to notice a 




4.8 BLOOD AND URINE BIOCHEMISTRY 
4.8.1 Amino-Terminal Pro B-Type Natriuretic Peptide 
NT-proBNP was unexpectedly higher in the placebo group at baseline. 
Importantly there were no differences in the baseline CMR-derived LV 
volumes or EF, NYHA functional class, BP or renal function between the 
groups. Large inter and intra-individual variation in NT-proBNP concentrations 
have been confirmed in patients with chronic HF and can sometimes 
complicate analysis.(213,214) Indeed some authors have made the 
observation that, paradoxically, trials with the most benefit in NT-proBNP-
guided therapy have had the least stringent NT-proBNP targets.(215) This is 
reflected by the ongoing uncertainty on the best cut-off values of BNP / NT-
proBNP particularly in chronic HF.  
The final NT-proBNP concentrations were not significantly different but 
remained heavily skewed. This makes interpretation very difficult; was there 
an improvement in the placebo group which started out with higher 
concentrations of NT-proBNP but then ending up no different from the 
dapagliflozin group? This, of course, goes against data suggesting SGLT2-
inhibitors are beneficial in HF.(167) Furthermore, there is no evidence within 
this study itself that suggest patients in the placebo group did better in any of 
the other parameters such as CMR-derived LV volumes or EF, NYHA 




Perhaps having a NT-proBNP cut-off in the inclusion / exclusion criteria may 
have mitigated this problem but it would have made recruitment much more 
difficult. This is discussed further in the study limitations.   
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4.8.2 Oxidized LDL 
There have been observations of increased LDL and HDL (with preserved 
ratios) in individuals treated with SGLT2-inhibitors.(163) As discussed in 
section 1.6.5 above, SGLT2-inhibiton shifts metabolism towards increased 
lipolysis. The activation of lipoprotein lipase and hepatic triglyceride lipase 
results in increased small dense LDL which are more prone to oxidation than 
the large buoyant type of LDL.(216) This could explain our observation of 
higher oxi-LDL levels in the dapagliflozin group.  
Of course, oxi-LDL has been implicated in the pathophysiology of a number of 
chronic diseases including metabolic syndrome and atherosclerosis. In those 
scenarios the metabolic pathways involved in the generation of oxi-LDL are 
quite different to those generated by SLT2-inhibiton.(217) It is important to 
recognise that oxi-LDL are merely surrogate markers of the various 
biochemical processes occurring in the body. In the case of this study it may 




4.8.3 Haemoglobin A1C 
There was no significant difference in the HbA1c levels between both groups. 
The efficacy of dapagliflozin in lowering HbA1c has been confirmed; 10mg 
once daily dapagliflozin alone or in combination with other anti-diabetes 
medications reduce HbA1c between 0.58% to 1.11% in patients with 
T2DM.(133) Although HbA1c was a secondary outcome measure, the 
REFORM trial was not sufficiently powered to assess this.  
Interestingly, subgroup analysis from the EMPA-REG trial showed that the 
efficacy of empagliflozin in reducing CV mortality, all-cause mortality and HF 
hospitalisation was independent of the degree of change in HbA1c. Indeed, it 
was seen even when HbA1c reduction did not meet thresholds for clinically 
meaningful reduction as defined by the ADA, EASD or US-FDA.(218)  
This suggests that the cardioprotective effects of SGLT2-inhibitors are 
unrelated to glycaemic control and perhaps in the future, SGLT2-inhibitors 
may no longer be classed as a diabetic drug.   
This revisits the perennial debate regarding the role of glycaemic control in CV 
outcomes. Indeed the VADT,(80) ADVANCE(81) and ACCORD(82) trials are 
some that have shown no benefits, and in some cases increased harm, 
amongst those undergoing intensive glucose lowering therapy. The 
mechanisms behind these findings are outside the scope of this work.  
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4.8.4 Urinary sodium  
Urinary sodium excretion was significantly lower in the dapagliflozin group. 
Although one would expect an increase in urinary sodium excretion in this 
group due to the mechanism of action of dapagliflozin (as discussed in section 
1.6.3), this was not observed.  
Although appearing paradoxical at first glance, the simple explanation for this 
observation is the change in furosemide dose. As noted in section 3.6, there 
was a near halving of the average daily loop diuretic dose and 50% of patients 
in the dapagliflozin arm had either reduced or stopped loop diuretic therapy. 
Loop diuretics have a potent natriuretic effect and this is the very likely cause 




4.9 SAFETY   
4.9.1 Renal function 
There were more cases of major worsening of renal function in the 
dapagliflozin group (8 vs 0; p=0.008). Major worsening was arbitrarily defined 
as more than 20% increase in creatinine or eGFR less than 45 ml/min/1.73 m2 
in two readings at least 1 week apart. It is important to note that this 
derangement in renal function was reversible by reducing the loop diuretic 
dose and resolved in all 8 cases without the need to withhold trial medications.  
Indeed, all SGLT2-inhibitors cause an initial rapid decline in eGFR which then 
recovers gradually.(219) The mechanism for this is the increased 
tubuloglomerular feedback due to higher sodium delivery to the macula densa 
(as a result of inhibition of the SGLT2 transporter in the proximal convoluted 
tubules). This feedback results in selective vasoconstriction of the afferent 
glomerular arterioles which reduces renal blood flow, thereby lowering the 
transglomerular pressure gradient. The lower pressure results in a lower eGFR 
but this does not necessarily imply renal dysfunction, in fact this is a reno-
protective effect.(220-222) ACE-I / ARB achieve reno-protection via a similar 
mechanism of lowered transglomerular pressure by selectively dilating the 
efferent arteriole. Indeed, when both drugs are used together, they could 
cause a significant drop in the transglomerular pressure, but this plateaus and 
recovers over time.  
As this was the first time SGLT2-inhibitor therapy was used in the HF 
population, in which renal dysfunction is fairly common, (and also because the 
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lower limit for use of dapagliflozin is 45ml/min/1.73 m2) we wanted to ensure 
safety was prioritised, hence why we had to act when a participant fulfilled 




4.9.2 Genital infections / urinary tract infections 
Genital infections are an important concern when using SGLT2-inhibitors and 
can, in some instances, result in significant morbidity and even mortality. The 
US-FDA recently issued a warning for increased risk of Fournier’s gangrene - 
an extremely rare form of necrotising fasciitis, usually in males, affecting the 
perineum that frequently requires wide surgical debridement and is sometimes 
life threatening. They report 12 cases of Fournier’s gangrene in patients taking 
SGLT2-inhibitors the 5 years between 2013 and 2018. Five patients were 
female, and all required surgical debridement (some requiring multiple 
disfiguring surgeries) and one patient died. In contrast, there were only 6 cases 
of Fournier’s gangrene (all male) in the last 30 years in all other classes of anti-
diabetic therapies combined.(223) Gadzhanova and colleagues also 
demonstrated the risk of genital infection such as vulvovaginal infections, 
vulval abscesses, balanitis, male and female candidiasis was 3.5 times more 
likely with the use of SGLT2-inhibitors compared to DPPIV-inhibitors, while 
there was no difference in the incidence of UTI.(224)    
In REFORM, the small cohort and short observation period meant that there 
was no statistically significant difference in the incidence of genital infections 
or UTI, although there were numerically more instances of these (5 vs 2) in the 
dapagliflozin arm. Two patients had recurrent episodes of infection, both were 
in the dapagliflozin arm. All instances were treated by GPs using standard anti-
bacterial / anti-fungal therapy over the usual treatment duration. Study drug 
was not withheld.   
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4.9.3 Others   
There was no difference in the incidence of all-cause deaths, CV deaths or 
acute coronary syndrome between groups, if anything there were more 
instances of these events in the placebo group.  
There was one instance of cancer recurrence in the dapagliflozin group and 
one case of new diagnosis of cancer in the placebo arm, none were breast or 
bladder cancers which were an initial concern in the preclinical stages of 
dapagliflozin and canagliflozin development.(225) 
We did not observe any instances of euglycaemic diabetic ketoacidosis or 





5. STUDY STRENGTHS AND LIMITATIONS  
5.1 STUDY STRENGTHS  
5.1.1 Trial design 
The REFORM trial was designed specifically to test the mechanistic effects of 
dapagliflozin in a population of patients with HF. The design was robust and 
comprehensive as it looked at various aspects of HF which included the 
current gold-standard of CMR-derived measures of LV remodelling, a battery 
of biomarkers, body composition analysis, measures of effort tolerance as well 
as quality of life measures. The observation period of 1 year is more than other 
similar studies of LV remodelling which range between 3 to 6 
months,(200,201) allowing for adequate time for remodelling to fully manifest 
itself, and more importantly, that it is sustained after 1 year of therapy.  
5.1.2 Reliability and reproducibility of cardiac MRI  
CMR is the current gold standard for measuring parameters of LV remodelling. 
It has two distinct advantages over echocardiography; firstly, its protocol-
based image acquisition ensures high fidelity measurements between the two 
readings a year apart as well as reduces the intra-observer variability. 
Secondly, it generates highly accurate and reproducible measurements that 
reduces the inter-observer variation and allows for a smaller sample size while 
maintaining statistical power.   
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5.1.3 Breadth of biomarkers measured   
The REFORM trial measured a host of blood and urine markers, allowing for 
a comprehensive analysis of the biochemical changes induced by 
dapagliflozin in the context of HF. It enhanced the safety of the trial (with 
regular NT-proBNP measurements in all visits allowing for early detection of 
HF decompensation), allowed for a possible explanation for some of the 
unanticipated observations (e.g. differential effects of dapagliflozin due to 
improved myocardial energetics from increased ketosis) as well as generating 
some new avenues of research (e.g. urinary sodium excretion and the effects 
of renal free water and solute handling with concomitant use of loop diuretics 
and SGLT2-inhibitors, which is a study currently being conducted by our 




5.2 STUDY LIMITATIONS 
5.2.1 Adjustment of loop diuretic dose  
One significant limitation of the REFORM trial was to do with the adjustment 
of loop diuretic dose. As this was the first clinical trial conducted in a cohort of 
patients with HF who were on established loop diuretic therapy, we were 
required by the MHRA to be cautious and include the allowance to modify (up 
or down titrate) the concomitant diuretic therapy. (At the time of conception of 
this trial, manufacturers recommended avoiding concomitant use of loop 
diuretics and SGLT2-inhibitors due to lack of data on the diuretic effects of 
SGLT2-inhibitors). Indeed we did see half of patients in the dapagliflozin group 
needing to reduce or stop their loop diuretic therapy, primarily due to transient 
impairment of renal function (which we now know, is due to increased 
tubuloglomerular feedback and is simply part of the pharmacodynamics of 
SGLT2-inihbition – see discussion on renal safety in section 4.9.1).   
Unfortunately, this may have also confounded the overall volume and blood 
pressure effects of dapagliflozin and could be the reason why no difference 
was seen in the LV volumes, mass and total body water composition between 




5.2.2 Heterogeneity of heart failure severity   
The eligibility criteria for the REFORM trial was a prior diagnosis of HF with 
echocardiographic evidence of at least mild LV dysfunction (LVEF<45%). The 
trial protocol did not require a screening echocardiogram to be performed prior 
to recruitment and, because the CMR images were only batch-analysed at the 
end of the trial, patients who strictly did not fulfil criteria at the time of 
recruitment could not be identified. With an average duration of HF of 6.24 
years, and a majority of the cohort on evidence-based anti-HF therapy, it is 
conceivable that some patients may have had improvements in their LV 
function since their last clinic echocardiogram. This was reflected by the wide 
range of CMR-derived LVEF at baseline (20.0% to 75.1%). A further reason 
for this discrepancy may be the result of operator variability and lower accuracy 
of echocardiography compared to CMR.  
This heterogeneity in the severity of LV dysfunction may have diluted the 
power of the primary outcome measure, contributing to the overall neutral 
outcome. Perhaps mandating a screening echocardiogram or including a 
baseline CMR exclusion criteria may have mitigated this problem. However, if 
the findings of the exploratory analysis hold true, (i.e. there is a differential 
effect of dapagliflozin favouring HFpEF) then having a cohort of homogenously 
poor LV function would not have identified this effect – this ‘shortcoming’ in 




6. FUTURE DIRECTIONS AND CONCLUSIONS 
Given the unexpected but consistent benefit of SGLT2-inhibitors in the HF 
population, it is tantalising to consider if these benefits persist in the non-
diabetic HF population. Indeed, the DAPA-HF (NCT03036124) and 
EMPEROR-Reduced (NCT03057977) trials are large multicentre studies 
looking at the effects of dapagliflozin and empagliflozin respectively on hard 
outcomes such as CV death and HF hospitalisation in an exclusively HFrEF 
population regardless of whether T2DM is present or not.  
There is also interest in the notoriously difficult to treat population of HFpEF; 
with the PRESERVED-HF study (NCT03030235) using dapagliflozin in 
patients with HF and LVEF>45% plus elevated natriuretic peptides (regardless 
of diabetes status) to look for changes in NT-proBNP concentration and 
echocardiographic parameters over a 12-week period. The far more ambitious 
EMPEROR-Preserved (NCT03057951) trial is looking into a similar 
population, using empagliflozin, with a composite primary outcome of CV 
death or HF hospitalisation over a 38-month period. If such a benefit is seen, 
this will be the first drug to have a benefit in hard outcomes in the HFpEF 
population. Perhaps the signal of potential benefit in this population that was 
identified in the REFORM cohort will encourage even more interest in this 
area.  
There are also some mechanistic studies looking into the cardio-renal effects 
of SGLT2-inhibition. The EMPA study (NCT03027960) is performing a detailed 
analysis of natriuresis (using ion selective electrodes) and blood volumes 
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(using radio-labelled albumin) in a small group of patients with HF and stable 
loop diuretic therapy. The RECEDE-CHF (NCT03226457) trial is another 
project by our laboratory studying the combined effects of empagliflozin and 
loop diuretic therapy on the renal free water and sodium handling 
characteristics of patients with HF.  
In conclusion, this work has explored the use of SGLT2-inhibitors in patients 
with T2DM and HF. By conducting the REFORM trial we confirmed, for the first 
time, that the effects of dapagliflozin on weight, BP, diuresis, Hb/Hct and 
ketones that were previously demonstrated in the T2DM population has 
remained consistent in patients with HF as well. However, there was no effect 
on the measures of LV remodelling, although there was a signal for potential 
benefit in a subgroup of patients with LVEF ≥45%. Some of the hypothesis-
generating findings of REFORM are already being investigated, such as the 
cardio-renal effects of uninterrupted loop diuretic therapy with SGLT2-inhibiton 
as well as the potential benefits of SGLT2-inhibition in patients with HFpEF. 
The REFORM trial was the first to ask the question about potentially using the 
SGLT2-inhibitor class in HF and has paved the way for future study into this 
and, perhaps, even the future ‘re-designation’ of this drug class into a primarily 
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Struthers, C.C. Lang. Research into the EFfect Of SGLT2 inhibition on left 
ventricular Remodelling in patients with heart failure and diabetes Mellitus 
(REFORM) Trial Rationale and Design. Cardiovascular Diabetology, 2016; 
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10.2337/db18-256-OR) 
2. European Society of Cardiology Congress (2018) – Poster presentation 
European Heart Journal. 2018; 39 (suppl1) (doi: 
0.1093/eurheartj/ehy564.P905)  
3. Scottish Society of Physicians Autumn Meeting 2018 – Oral 
presentation.   
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